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discoveries, is not 'Eureka!', but 'That's funny...'  
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Hemophilia is a hereditary clotting disorder which is caused by a deficiency of factor VIII 
(hemophilia A) or IX (hemophilia B). In the Netherlands the prevalence is around 10 per 
100,000, resulting in about 1600 patients1. The severity of the disease is determined by the 
residual clotting factor activity. Patients with mild hemophilia (>0.05-0.40 IU/ml) show little 
spontaneous bleeding and bleed excessively only after major trauma; patients with moderate 
hemophilia  (0.01-0.05 IU/ml) may show excessive hemorrhages after minor trauma, while 
severe hemophilia (<0.01 IU/ml) is characterized by major bleeding occurring spontaneously 
or after minor trauma. Frequent bleeding in joints results into damage of the synovial tissue 
and arthropathy. Hemophilia is a genetic recessive X-linked trait and therefore patients are 
mostly men. Female family members can be carriers of the disorder, which is characterized by 
a 25% chance of having a son with hemophilia, and a decreased clotting factor activity level.  
  
History 
Although effective treatment has only become available in the recent decades, hemophilia was 
known to the ancient world. The earliest written references to what appears to be hemophilia 
are encountered in Jewish texts of the second century AD. Rabbinical rulings exempted male 
boys from circumcision if two previous brothers had died of bleeding after the procedure2. 
The first modern description of hemophilia is attributed to Dr John Conrad, who clearly 
appreciated the three cardinal features of hemophilia: an inherited tendency of males to 
bleed3. However, the first use of the word "hemophilia" appears in an account of the condition 
written in 1828 by Hopff (Über die haemophilie oder die erbliche Anlage zu tödliche 




members of royal families in Europe were affected by it. Queen Victoria had no ancestors 
with the condition but soon after the birth of her eighth child, Leopold in 1853 it became 
evident that he had hemophilia. Two of Queen Victoria's daughters were also carriers of 
hemophilia. The condition was transmitted through them to several Royal families. Perhaps 
the most famous affected individual was the son of Tsar Nicolas II of Russia, Tsarevich 
Alexis, who was born in 19044.  
 
Treatment and complications 
Many reputable scientist claimed early success in treatment with unusual substances. As 
recently as 1964 a report in Lancet claimed that peanut flour was effective for the treatment of 
hemophilia5. The first hint of success came from Dr R.G. Macfarlane in 1934, who discovered 
that snake venom could accelerate the clotting of hemophilic blood6. Plasma derived factor 
VIII and IX preparations became available in the early 1960s7.  Ever since the discovery by 
Dr Judith Pool of cryoprecipitate, replacement therapy with factor concentrates has been the 
most important component of hemophilia care. This treatment rapidly improved the medical 
and social situation of patients with hemophilia and considerably increased life expectancy8,9.  
In the early 1980s major side-effects became manifest when many patients became infected 
with the human immunodeficiency virus (HIV)10. Moreover, of all patients treated before 
1992 with plasma-derived clotting factor preparations, 80 percent became infected with 
hepatitis viruses11. Today, clotting factor preparations are virtually safe regarding blood-borne 
viruses12, and the risk of hepatitis and HIV transmission must be considered negligible, 
whereas the development of neutralizing antibodies (‘inhibitors’) against the infused factor 
VIII or IX is an important issue13,14.   
The characterisation and cloning of the factor VIII gene in 1984 led to the availability of 




human blood and therefore even theoretically incapable of transmitting human blood-borne 
pathogens, has further stimulated the use of prophylactic treatment. In the Netherlands since 
the late 1970s treatment of hemophilia has consisted of the intravenous infusion of clotting 
factor concentrates performed either on demand (at the moment of bleeding) or 
prophylactically. Prophylactic treatment is primarily prescribed to patients with severe 
hemophilia. The rationale for prophylaxis in hemophilia is that patients with a factor level of 
0.01-0.04 IU/ml rarely develop chronic joint changes. By maintaining the plasma 
concentration of clotting factors at a level above 0.01 IU/ml hemophilia can be converted 
from a severe to a milder form15-17.  
 
Outline of this thesis 
The main aim of this thesis was to study the effects of hemophilia treatment on both the 
medical situation and social functioning of hemophilia patients. Effective treatment of 
hemophilia has been available since the late 1960s7 and offered patients better prognosis  but 
also had a large negative impact through blood-borne viruses.  This has been described in 
Chapter 2. In Chapter 2.2 we studied mortality, causes of death and life expectancy in Dutch 
hemophilia patients between 1992 and 2001.With this study we complete the inventory of 
mortality in patients with hemophilia over thirty years, describing the period before18, 
during19 and after the use of potentially contaminated clotting products. In chapter 2.2 the 
results of the Hemophilia in the Netherlands-5 (HiN-5) project are described and data are 
compared to the previous surveys. This chapter focuses on both medical issues, such as 
haemorrhages and joint problems but also on social aspects such as absence from work and 
school. Social functioning and health related quality of life of hemophilia patients compared 
to the general population are described in Chapter 2.3. In Chapter 2.4 clinical characteristics 




introduced in the early 1990s. Despite the serious side effects of plasma-derived clotting 
products these new products were not accepted as quickly as expected. In Chapter 2.5 factors 
influencing the use of recombinant factor VIII were studied.  
Female relatives of male patients can be carriers of hemophilia; besides its impact on family 
planning carriership of hemophilia may also lead to bleeding problems. Chapter 3 evaluates 
whether carriers of hemophilia have more bleeding problems than to non-carriers, with a 
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We studied mortality, causes of death and life expectancy of hemophilia patients between 
1992 and 2001. We compared these findings with those of previous cohorts, together 
spanning the periods before, during and after the use of potentially contaminated clotting 
products.  
We performed a prospective cohort study among 967 patients with hemophilia A and B. 
Death rates, overall and cause-specific, were compared to national mortality figures for males 
adjusted for age and calendar period as Standardized Mortality Ratio (SMR’s). Between 1992 
and 2001, 94 (9.7%) patients had died and 2 patients were lost to follow-up (0.2%). Mortality 
was 2.3-times higher in hemophilia patients than in the general male population (SMR 2.3 95 
% confidence interval 1.9-2.8). In patients with severe hemophilia life expectancy decreased 
from 61 to 59 years. Exclusion of virus-related deaths resulted in a life expectancy at birth of 
72 years. 
AIDS was the main cause of death (26%) and 22% of deaths were due to hepatitis C. In 
patients not affected by viral infections mortality was still slightly higher than in the Dutch 
male population. Thus mortality of patients with hemophilia is still increased; this is largely 





Hemophilia is an X-linked genetic bleeding disorder caused by deficiency of coagulation 
factor VIII (hemophilia A) or factor IX (hemophilia B). Due to the hereditary pattern of 
hemophilia patients are almost invariably male, while women can be carriers of the disease. 
Severe forms are characterized by major bleeding occurring spontaneously or after minor 
trauma. These hemorrhages often occur into joints eventually causing disabling arthropathy1.  
 
Before the introduction of clotting factor preparations the mean life expectancy of patients 
with hemophilia was less than 30 years2, and patients mostly died of intracranial3-5 or other 
hemorrhages. Since the 1960s factor VIII and IX preparations have been available for the 
treatment of hemophilia. This rapidly led to medical and social improvements, with a decrease 
in the frequency of hemorrhages and considerably improved life expectancy of patients with 
hemophilia.  
 
Despite these positive developments, mortality of patients with hemophilia again increased 
during the 1980s. In 1982, the first case of acquired immunodeficiency syndrome (AIDS) in a 
patient with hemophilia was reported6,7. Since then many more cases have been reported 
worldwide, of whom many have died. In addition, about 80 percent of the patients treated 
with clotting factor products before 1992 became infected with hepatitis C8,9. The full 
consequences of hepatitis C infections are only recently being recognized10 
 
Since 1985, products have been safe for HIV and since 1992 also for the transmission of 
hepatitis C (HCV). Today, the most important complication of clotting factor treatment is the 
development of neutralizing antibodies (inhibitors) against factor VIII or IX11.   
 
Mortality and causes of death in patients with hemophilia, 1992-2001 
 
21 
Few studies have reported on mortality in the total population of hemophilia patients after the 
period of the risk of viral infection transmission. Several studies have aimed at describing 
mortality within a specific subpopulation, such as hemophilia patients infected with HIV12-14.  
This study completes the inventory of mortality in patients with hemophilia over the last 30 
years in the Netherlands, which describes the period before15, during16 and after the use of 
potentially contaminated clotting products.   
 
Objectives 
We studied mortality, causes of death and life expectancy of hemophilia patients between 
1992 and 2001. We compared these findings with those of previous cohorts from our national 
surveys on hemophilia, starting in 1972.  
 
Material and methods 
Study design 
A prospective cohort study was performed as part of a survey among all known patients with 
hemophilia in the Netherlands. In June 1992, we sent questionnaires to all patients who were 
listed with the Netherlands Hemophilia Society, with the hemophilia treatment centers, or on 
updated mailing lists from previous surveys in 1972, 1978 and 198517. For this national study, 
1292 patients received a questionnaire of whom 967 (75%) responded. Vital status at the end-
of study date was determined by the response to the survey of 2001, from the attending 
physician or from municipal population registries. Of patients who had died during follow-up 
dates of death were obtained from municipal registries and physicians. This study is part of 
the Hemophilia in the Netherlands-5 study, which has been approved by the Committee of 





Cause of death 
The causes of death were obtained from treating physicians or general practitioners and were 
categorized according to the tenth revision of the International Classification of Diseases, 
Injuries, and Causes of Death-10 (ICD-10)18. Overall and cause-specific mortality of the 
general Dutch male population was retrieved from the Central Bureau of Statistics19. Date of 
birth, severity of hemophilia, HIV status and information on inhibitory antibodies were 
derived from the self-reported answers to the questionnaire. Severity of disease and type of 
hemophilia were verified with the patients’ physicians. Severity of hemophilia, depending on 
the residual clotting factor activity was categorized as severe (< 0.01 IU/ml factor VIII or IX), 
moderate (0.01-0.05 IU/ml) or mild (>0.05-0.40 IU/ml factor VIII or IX). The HIV status was 
based on self-reported answers of the patients. If patients were born after 1985 or if they 
reported no treatment with clotting factor between 1979 and 1985, HIV status was considered 
to be negative. 
 
Statistical analysis 
Standardized Mortality Ratios (SMR’s) were calculated to estimate the rate of overall and 
cause specific death of patients with hemophilia relative to that of the general male population 
adjusted for age and calendar period.  The SMR is the number of observed deaths divided by 
the number that was expected if the mortality rate in the cohort, with its specific age-
distribution, was the same as that in the general population. Patients were followed from the 
1st of June 1992 to the 1st of July 2001. We used mortality rates from the Dutch general male 
population between 1992 and 2001. Ninety-five percent confidence intervals (CI) were based 
on a Poisson distribution for the observed number of deaths.  To put our findings into 
perspective they were compared to those of the previous cohort studies between 1972-198515 
and 1985-199216. For this comparison mortality ratios were calculated by direct 
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standardization using WHO standardization weight factors 
(http://www3.who.int/whosis/discussion_papers/pdf/paper31.pdf).  
Two methods were used to exclude the effect of viral infections on mortality 1) exclusion of 
patients who reported to be HIV positive in 1992 and 2) censoring patients of whom death 
was a result of HIV (AIDS) or HCV (liver cirrhoses, hepatocellular carcinoma) at the date of 
death. Cause-specific SMRs were calculated by studying the specific cause of death as 
endpoint and censoring patients with other endpoints. Median life expectancy was calculated 
with left truncated survival analysis and was expressed as the median age at which cumulative 
survival was 50%.  
 
Results  
Table 1 shows the general characteristics of the patients with hemophilia in 1992. Between 
1992 and 2001 the total number of patient-years of follow-up was 8868 (mean 8.6 (range 0-9) 
yrs), 94 patients died and two patients were lost to follow-up. Of all 967 patients in the cohort, 
796 (87%) patients had hemophilia A and 125 (13%) patients had hemophilia B; 386 (39%) 
patients had severe hemophilia, 167 (17%) patients had moderate hemophilia and 414 (43%) 
had mild hemophilia; the mean age was 32 (range 0-82) years; 50 (5.2%) patients reported to 
have inhibitory antibodies against the deficient clotting factor; and 53 patients (5.5%) were 
HIV positive. The mean age at death was 52 years, with a range from 14 to 83 years. In 20% 
of deceased patients the presence of an inhibitor was reported at time of death. 
The expected number of deaths during this same calendar period was 39. The standardized 
mortality ratio (SMR) was 2.3  (CI 1.9-2.8), indicating that the overall mortality rate of 
patients with hemophilia was two times higher than in the general male population. In patients 




Table 1. General characteristics of participants at entry (1992) 
 N=967 
  
 Age (yrs) 32 (0-82) 
  
Severity of disease  
 Severe (<0.01 IU/ml) 386 (40) 
 Moderate (0.01-0.05 IU/ml) 167 (17) 
 Mild (>0.05-0.40 IU/ml) 414 (43) 
  
Type of hemophilia  
 Hemophilia A 796 (87) 
 Hemophilia B 171 (13) 
  
HIV infection 53 (6) 
  
Inhibitor present* 50 (9) 
  
Data presented are means(range) or numbers(percentages) 
* Inhibitory antibodies against the deficient clotting factor 
 
Standardized mortality ratios taking into account HIV infection and severity of disease are 
shown in Table 2. Restriction of the analysis to patients not infected with HIV revealed that 
mortality in patients with hemophilia was 70 percent higher than that in the general 
population (SMR 1.7, CI 1.3-2.7). After exclusion of deaths related to either HIV or HCV 
mortality rate among patients with hemophilia was 20 percent higher than among the general 
population (SMR 1.2, CI 0.9-1.6), in patients with severe hemophilia this was 40% (SMR 
1.4,CI 0.8-2.4). 
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Table 2. Standardized Mortality Ratios (SMR) for severity and type of hemophilia taking into account the 
HIV status 
 
 Observed deaths* All patients 
SMR (95% CI)† 
HIV negative patients‡ 
SMR (95% CI) 
    
All 94 2.3 (1.9-2.8) 1.7 (1.3-2.1) 
    
Severity    
 Severe 47 5.1 (3.8-6.8) 2.8 (1.9-4.2) 
 Moderate 15 2.6 (1.5-4.3) 2.3 (1.3-3.9) 
 Mild 32 1.3 (0.9-1.9) 1.2 (0.8-1.6)  
    
Type of hemophilia    
 Hemophilia A 81 2.3 (1.9-2.9) 1.7 (1.4-2.2) 
 Hemophilia B 13 2.3 (1.3-4.0) 1.3 (0.6-2.7) 
*Data presented are absolute numbers of observed deaths 
† 95% Confidence Interval 
‡ Only including patients who reported to be HIV negative or patients who were born after 1985 
 
Direct standardization of mortality rates made comparisons between time periods possible. 
We found that mortality of the whole cohort of patients with hemophilia did not change over 
three time-periods. Relative rate, compared to subjects without hemophilia, i.e., the general 
population, was 1.6 between 1972 and 1985, 2.1 between 1985 and 1992 and it was 2.0 
between 1992 and 2001. However, stratification for severity of hemophilia revealed that the 
rate of death of patients with severe hemophilia increased over the last three decades. It was 
three times higher than the rate in subjects without hemophilia during the period between 
1985-1992 and it was 4.5 times higher during the last period of follow-up. 
 
Cause specific mortality 
Table 3 shows the primary causes of death between 1992 and 2001. Between 1992 and 2001 
24 (26%) patients died of AIDS of whom 22 (87.5%) had severe hemophilia. In 21 patients 




transplantation were the cause of death, while in five patients a hepatocellular carcinoma or 
metastasis of a liver carcinoma was reported.    
 
Table 3. Primary causes of death according to the ICD-10 classification 
 






    
AIDS† (B20-34) 0 (0) 12 (27) 24 (26) 
    
Hepatitis C  - - 21 (22)‡ 
 Hepatocellular carcinoma (C22) - - 5 (5) 
 Chronic liver disease (K70, K72.9, K73-K74, C78.7) 0 (0) 5 (11) 10 (11)§ 
     
Diseases of the circulatory system  (I00-I99) 4 (9) 10 (24) 16 (17) 
   Ischemic heart disease (I20-I25) 1 (2) 0 (0) 6 (6) 
  Cerebrovascular disease (I60-I69) 3 (7) 9 (20) 4 (5) 
    
Malignancies (C00-D48) 13 (30) 7 (15) 12 (15) 
    
Hemorrhages  20 (47) 1(2) 5 (5) 
    
Other (A40.3, A41.9, J18, R06.8, R54) or not natural 
cause of death (T14.9, V01-Y98)   
3 (5) 6 (9) 13 (11)║ 
    
Sudden death, cause unknown (R96, R99) 3 (7) 4(9) 3 (3) 
    
*ICD-10=International Classification of Diseases, 10th revision,  
†AIDS = Acquired ImmunoDeficiency Syndrome  
‡2 patients due to complications of livertransplantation, 5 of hepatocellular carcinoma, 10 of chronic liver disease, in four 
patients only hepatitis C mentioned as cause of death  
§ In four patients a hemorrhagic shock was reported  
||1 patient died due to ‘natural causes’,  
 
A hemorrhagic shock resulting from end-stage liver disease (n=10) was reported in five 
patients. A co-infection with HIV and HCV was observed in five of the deaths resulting from 
hepatitis C. Mortality due to AIDS and chronic liver disease was highest in patients with 
severe hemophilia although these causes of deaths were also observed in patients with 
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moderate hemophilia (n=4, 27%). Among patients in whom death was not related to HCV or 
HIV (n=49) the main cause of death was hemorrhage (13/49), which also includes intracranial 
hemorrhages (n=4) and hemorrhages resulting from trauma (n=4). Compared to the Dutch 
male population the incidence of death from intracranial hemorrhages is higher in patients 
with hemophilia, 0.1 per 1000 person-years and 0.5 per 1000 person years respectively. Death 
from malignant neoplasm (including hepatocellular carcinoma) was reported in 22% of 
patients. Although the percentage of patients with mild hemophilia that died as a result of 
malignancies was higher than in the Dutch male population, at 41% vs. 31%, overall mortality 
of malignancies was lower, at 19% vs. 31%. Death due to disease of the circulatory system 
was lower in patients with hemophilia than in the Dutch male population 17% and 28% 
respectively. The cause of death remained unknown in three patients.   
The proportion of patients that died of AIDS stayed constant during the last two periods of 
follow-up. Death due to hepatitis C increased compared to the period between 1985 and 1992, 
11% vs. 22%. No deaths of AIDS or hepatitis C were reported in the first period of follow-up 
(1972-1985). The occurrence of cerebral vascular disease was lower than in 1986-1992, when 
it accounted for 20% of all deaths compared to 4% in the current period of follow-up.   
 
In Table 4 cause-specific standardized mortality ratios are shown. Mortality due to viral 
infections was 117 times higher than in the general population, and mortality due to HCV was 
16 times (SMR 16.1, CI. 7.7-33.8) higher in patients with hemophilia than in the general 





Table 4. Primary cause of death specific Standardized Mortality Ratios 
 










   
Hepatitis C   
Hepatocellular carcinoma (C22) 4 17.2 (5.2-35.9) 
Chronic liver disease 
(K70, K72.9, K73-K74) 
10 16.1 (7.7-33.8) 
   
Ischemic heart disease (I20-125) 6 0.5 (0.2-1.1) 
Cerebrovascular disease (I60-I69) 4 1.0 (0.2-2.2) 
   
Malignancies 18 1.5 (1.0-2.5) 
Malignancies (no liver) 12 1.1 (0.6-1.9) 
   
*Absolute numbers of death observed 




Life expectancy was calculated stratified for severity of hemophilia and based on 
extrapolation from the observed death rates (Table 5). In patients with severe hemophilia a 
life expectancy of 59 years at birth was observed, and censoring of patients that died due to 
virus infections resulted in a life expectancy of 71 years in patients with severe and moderate 
hemophilia. Life expectancy at birth of patients with mild hemophilia was lower than that of 
the male population, at 73 years compared to 76 years. After exclusion of viral infections the 
life expectancy of mild hemophilia patients was 75 years.   
The overall life expectancy of the patients with hemophilia did not notably change between 
1972 and 2001. The life expectancy of patients with severe hemophilia, however, decreased 
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from 63 to 59 years. For patients with moderate hemophilia life expectancy increased from 65 
to 67 years. 
 
Table 5. Life expectancy (years) according to severity in 30 years of follow-up 
 1972-1985 1985-1992 1992-2001 




 HIV and HCV† 
negative 
N=967 
All patients (years) 66 68 67  70 74  
      
Dutch males 71 74 76 76 76 
      
Severity of hemophilia 
 Severe  
(<0.01 IU/ml) 
63 61 59  70 71  
 Moderate  
(0.01-0.05 IU/ml) 
65 65 67  71 75  
 Mild  
(>0.05-0.40 IU/ml) 
- 74 73  73 75  
      
Type 
Hemophilia A - 69 68  70 73 
Hemophilia B 
 
- 64 60  73 --‡ 
* Patients of whom HIV status was negative or who were born after 1985 
† HIV and HCV related deaths are censored 





During the last decade hemophilia was characterized by an excess mortality as compared to 
the general population. Human Immunodeficiency Virus (HIV) infection was responsible for 
the largest number of deaths (n=24, 26% of deaths) and 16% of deaths were due to 
hepatocellular carcinoma or chronic liver disease resulting from a HCV infection. Overall, 
patients with severe hemophilia had a five-fold higher risk of death than men in the general 
population. Without the effects of HIV and HCV the rate of death among patients with severe 
hemophilia was 1.4-fold higher than expected. The remaining excess risk in all likelihood 
results from hemorrhages.  Life expectancy of patients with severe hemophilia decreased 
compared to earlier studies, mostly influenced by HIV. Patients with severe hemophilia not 
affected by hepatitis C or HIV had a life expectancy of 71 years, which can be compared to a 
life expectancy of the Dutch male population of 76 years.  
In the survey of 1992, 93% of all Dutch hemophilia patients were sent a questionnaire, of 
whom 75% participated in the survey, and were subsequently followed for this study on 
mortality. Only two patients were lost to follow-up and we were able to retrieve 96% of all 
causes of death. This resulted in a complete cohort comprising a large population of 
hemophilia patients. There was no difference in severity of hemophilia or mean age between 
the responding and non-responding population to the questionnaire of 1992, and therefore we 
consider our data to be generalizable to the Dutch hemophilia population. Theoretically, 
because the causes of death were reported by the treating hematologist or the general 
practitioner there may have been discrepancies with the general population data gathered 
through the Central Bureau of Statistics. We do not expect this to be of large influence. As 
always in research on life expectancy the findings may not hold for the present patients with 
hemophilia. Exclusion of effects of viral infections results in a reflection of the situation for 
patients not exposed to non-safe clotting products or not infected products. In our cohort no 
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deaths were reported in the youngest age-category between 0 and ten years. The youngest 
participant to this study was four months old, and therefore our study did not cover perinatal 
mortality. Due to limited information on the presence of inhibitory antibodies we have not 
been able to study the impact on mortality.  
 
Our study shows a two-fold increased mortality for patients with hemophilia; in patients with 
severe hemophilia this was even a five-fold increase. We estimated the future perspective by 
excluding death due to HIV or hepatitis C. There still appeared to be a trend towards a 
moderately but enduring increased mortality for patients with hemophilia, especially in severe 
hemophilia. As nowadays products are safe from transmission of HIV and hepatitis C, 
preventive efforts should focus on factors causing this remaining excess mortality. The most 
important factor is an increased risk of death of hemorrhages, either intracranial or resulting 
from trauma.  Although mortality of HCV and HIV is extensive and the numbers to compare 
with the general population are limited there seems to be a higher incidence of death from 
intracranial hemorrhages in patients with severe, moderate and mild hemophilia. This 
indicates the importance of adequate and specialized care for hemophilia patients. Although 
we also observed a high number of other hemorrhages, e.g., resulting from trauma we were 
not able to make a comparison with the general population.  A second factor of impact could 
be deaths due to hepatitis C that had not been reported as such. However, as the hepatitis C 
status is well known and a good registration is used by treating physicians this is probably of 
limited influence 
 
Over the last three decades causes of death of patients with hemophilia have changed; during 
the 1970s and early 1980s patients with hemophilia died mostly of intracranial hemorrhages, 




Netherlands the impact of HIV was relatively low through the use of predominantly products 
from local voluntary unpaid donors, AIDS was responsible for a quarter of all deaths during 
the 1990s. In the present follow-up period about 80% of deaths from AIDS occurred before 
1995, indicating that the impact of AIDS on mortality of patients with hemophilia is 
declining. This decreased influence is explained by a reduced number of survivors of an HIV 
infection, and by improved survival of patients infected with HIV through HAART therapy20. 
The effects of hepatitis C infections on mortality have increased considerably during the last 
ten years, and about 20% of deaths were due to the effects of hepatitis C, of which liver 
cirrhosis or liver failure were the most prevalent. Our study shows a highly increased risk of 
death of hepatocellular carcinoma, which is similar to a study by Darby et al in which a 20-
fold increased risk was reported in non-HIV infected patients with severe hemophilia21.  
Although the introduction of new treatment methods combining pegylated interferon with 
ribavirin will positively influence mortality of HCV infected patients the effects of HCV will 
remain to be present in those patients in whom this therapy failed.  For patients not affected 
by viral infections hemorrhage was still a relatively frequent cause of death. As this is similar 
to the period before the impact of viruses transmitted by clotting products we might conclude 
that the increased availability of clotting factor has not reduced the number of deaths due to 
hemorrhages. The number of deaths from malignant neoplasm was not higher than expected 
in this population. In concordance with earlier studies and findings by Rosendaal et al we 
observed a reduced rate of mortality of ischemic heart disease in patients with hemophilia22.  
 
Life expectancy of patients with severe hemophilia was lower during the last decade as 
compared to earlier observations. An important part of this decline is explained by death due 
to viral infections. When AIDS and hepatitis C deaths were excluded, life expectancy, 
improved but although the general life expectancy in European countries is approached it 
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remains to be lower especially in patients with severe hemophilia 23. Walker et al published 
the same observations in a Canadian population24.  After exclusion of viral infections patients 
with mild and moderate hemophilia have a life expectancy that is about equal to the average 
Dutch male population.  
 
Our data show that HIV and hepatitis C still largely influence mortality of hemophilia 
patients. The effects of hepatitis C will be present for many years to come. In patients with 
severe hemophilia not infected with viruses mortality is still 40 percent higher than in the 
general population. Although this suggests that the current patient with hemophilia benefits 
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Since the introduction of replacement therapy in the early 1960s by the infusion of plasma-
derived factor VIII and IX preparations important changes have occurred for hemophilia 
patients. We studied the medical and social developments over 30 years of hemophilia 
treatment.  
Since 1972 5 cross-sectional national postal surveys among all hemophilia patients in the 
Netherlands were performed, the latest in 2001. The prestructured questionnaires included 
items on treatment, the presence of inhibitory antibodies against factor VIII or IX, the annual 
number of bleeding episodes, use of inpatient hospital care and hepatitis C and HIV 
infections.  
Response rate in 2001 was 70%. Young patients (<16 years) with severe hemophilia showed 
the largest increase in use of prophylaxis, from 34% in 1972 to 86% in 2001. The occurrence 
of hemorrhages has gradually decreased. Hospital admissions decreased from 47% of all 
patients in 1972 to 18% in 2001.  
Our study shows that the treatment of patients with severe hemophilia in the Netherlands has 
focused on the use of prophylactic treatment, especially in children. This has resulted in a 
decrease in bleeding frequency and an improvement of the medical and social circumstances 






Hemophilia is a X-linked genetic bleeding disorder caused by deficiency of coagulation 
factor VIII (hemophilia A) or factor IX (hemophilia B). Severe forms are characterized by 
major bleeding after minor trauma. These hemorrhages often occur into joints eventually 
causing arthropathy, which is associated with physical and psychosocial impairment1.  
 
Since the introduction of replacement therapy in the early 1960s, the infusion of plasma-
derived factor VIII and IX preparations, important changes have occurred for hemophilia 
patients2,3. For patients with hemophilia mean life expectancy has increased over the years 
from lower than 30 years in 1960 to an almost normal life expectancy of 68 years in 19924,5. 
Prophylaxis was introduced in the Netherlands in the late 1960s6,7. As from the 1970s it 
became possible for patients to treat themselves at home and the introduction of clotting 
factor concentrates in 1978 further facilitated developments. Although the general superiority 
of prophylactic treatment over on-demand treatment has been demonstrated6,8,9, the question 
of when and in whom to start, and how to dose prophylactic therapy, remain a subject of 
discussion10.  Some believe that intensified on-demand treatment may be as effective as 
prophylaxis.  Arguments in favor of on-demand therapy include fewer exposures with a 
potential concomitant reduction in pathogen exposure, less financial burden for the family 
(depending on the health care system) and society and greater therapeutic maneuverability in 
times of reduced product availability11. Randomized clinical trials to compare cost-
effectiveness of prophylaxis and on demand treatment are ongoing12,13.  
 
Although treatment with clotting factor concentrate has enabled patients to participate fully in 
normal life, the infusion of plasma products also has had important adverse effects, such as 
infections with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and 




inhibitor development. Of the Dutch hemophilia patients who were treated with plasma-
derived clotting factors before 1985 17% became infected with the human immunodeficiency 
virus (HIV)2. Plasma-derived products have been safe for hepatitis B and HIV since 1985 and 
also for HCV since 1992 14.  
 
In 1995 recombinant FVIII products have been introduced in the Netherlands and have 
become increasingly used15, especially in previously untreated patients; along with the use of 
purified plasma-derived products, this minimizes the risk of transmission of HIV or HCV16. 
Today, the most important complication of clotting factor treatment is the development of 
neutralizing antibodies (inhibitors) against factor VIII or IX17.   
 
Objective   
In the Netherlands a series of 5 national postal surveys18,19 have been performed, from 1972 
onward. In this study we evaluated the most important medical and social developments over 
the last three decades of hemophilia treatment.  
 
Patients, materials, and methods 
Patients 
A nationwide postal survey was conducted in the Netherlands in 2001, following 4 previous 
surveys in 1972, 1978, 1985 and 199218,19. We contacted patients who were listed with the 
Netherlands Hemophilia Society and the hemophilia treatment centers and we updated 
mailing lists from previous surveys. In April 2001, 1567 questionnaires were sent to all 
known Dutch hemophilia patients, followed by 2 reminders. Response is given for all 
questionnaires that were returned, irrespective of diagnosis (i.e. hemophilia or other bleeding 




disorders or symptomatic carriers, this report is restricted to men with hemophilia A or B. 
The severity of hemophilia was classified according to residual percentage of factor VIII or 
IX clotting activity: severe (<0.01 IU mL), moderate (0.01-0.05 IU mL) or mild (>0.05-0.40 
IU mL). The self reported type and severity of hemophilia were verified with data from the 
treatment centers. The parents or caretakers completed the questionnaire if the patient was 
younger than 12 years.  
The five prestructured questionnaires that were used between 1972 and 2001 included many 
items that were identical: treatment modalities, the presence of inhibitors, the annual number 
of bleeding episodes, the use of inpatient hospital care, absence from school or work, degree 
of joint impairment, employment, and disability. The questionnaires differed on topical issues 
(e.g. home treatment in 1978 and AIDS in 1985). In the 2001 questionnaire items on hepatitis 
C and type of product were added.  




All analyses were stratified by the severity of hemophilia, and often by age category as well. 
As the clinical characteristics of hemophilia A and hemophilia B do not differ, we present 
combined results for hemophilia A and B. Data on the treatment modality, the number of 
bleeding episodes, the use of hospital facilities, and absence from school or work referred to 
the year that preceded the questionnaire surveys (2000).  Children were defined as patients 
younger than 16, adolescents as patients between 16 and 25 and adults as patients older than 
25 years. The use of prophylaxis refers to patients who received prophylaxis as their main 
treatment modality, excluding patients who received a combination of on demand treatment 
and prophylaxis during risk periods. Absence from school was calculated only for that part of 




the population that followed a full-time education. Absence from work was calculated for 
patients aged 16 to 65 who had a paid job (full-time or part-time). The inactivity ratio was 
calculated as the ratio of inactivity in the study population and inactivity in Dutch men. 
Patients that did not have a full-time or part-time paid job were defined as inactive.  
Descriptive statistics for age, the use of hospital facilities, absence from work and 
employment were compared to national figures for the general male population that were 
provided by the Central Bureau of Statistics Netherlands Statline database20. Self reported 
measures on joint impairment were obtained for a series of 16 joints which are, the neck, the 
left and right shoulder, the back, the left and right elbow, the left and right wrist, the left and 
right hand and fingers, the left and right hip, the left and right knee and the left and right 
ankle. The possible scores were 0 (no impairment), 1 (some impairment without daily 
problems), 2 (some impairment with daily problems), and a maximum of 3 (severe 
impairment with complete loss of function).  
 
From scores of the 16 separate joints a joint score was calculated with a minimum score of 0 
and a maximum score of 48 points. As joint impairment was reported most frequently in the 
ankles, elbow and knees these were analyzed separately. 
 
Results     
Response and patient characteristics 
Response was 70% in 2001, compared to 84% in 197219, 70% in 197821, 81% in 198522 and 
78% in 199218.  One hundred and ninety eight patients participated in all 5 surveys. Table 1 
shows the characteristics of participants in each of the 5 surveys. The mean age of 
participants increased from 21 years (median 19; range, 0-74 years) in 1972 to 35 years 




Table 1. Overview of characteristics of participants to the Hemophilia in the Netherlands studies obtained 
from self-reported data 
 
 
Values presented are medians( range) or number(%)   
*Of 33 patients severity was missing in 1972    
†All other patients are patients with hemophilia B  
 
 This was still somewhat lower than the mean age of Dutch men, which increased from 32 to 
37 years over the same period. Of all participants in 2001, 39% had severe hemophilia, 17% 
had moderate hemophilia, and 44% had mild hemophilia. In 23% of patients, the genetic 
inheritance pattern of the disease was that of isolated hemophilia: they had no other family 
members with hemophilia. This proportion had remained constant over the 30 years spanned 
by the surveys. Thirty-eight percent of patients with severe hemophilia were isolated patients, 
and 13% of patients with moderate hemophilia were isolated patients. 
 
 
 1972 1978 1985 1992 2001 
N 447 560 935 980 1066 
      
age (years) 19 (0-74) 23 (0-70) 28 (0-85) 31 (0-84) 36 (0-90) 
      
Severity of hemophilia      
 severe (<0.01 IU ml) 159 (36)* 245 (44) 384 (41) 387 (39) 420 (39) 
 moderate (0.01-0.05 IU ml) 83 (19) 106 (19) 175 (19) 173 (18) 176 (17) 
 mild (>0.05-0.40 IU ml) 172 (38) 138 (25) 376 (40) 420 (43) 470 (44) 
      
Type of hemophilia      
 type A† 377 (84) 481 (86) 801 (86) 853 (87) 925 (87) 
       
Hereditary pattern      
 sporadic hemophilia 112 (25) 128 (23) 237 (25)  195 (20) 246 (23) 
       
      





In 2001, 580 patients (54%) received treatment on-demand, and 305 patients (29%) 
prophylaxis, whereas 127 patients (12%) were treated on-demand at times and 
prophylactically at other times. For 54 patients (5%), no data were available about treatment, 
and most of these patients (n=45) had mild hemophilia. Prophylactic treatment was used 
mostly in children and adolescents with severe hemophilia (Table 2).  This group also 
showed the largest increase in use of prophylaxis, from 34% and 31% in 1972 to 86% and 
90% in 2001; for adults with severe hemophilia this increased from 14% in 1972 to 54% in 
2001.  A substantial proportion of adult patients (15/39, 38%), who now were treated on-
demand only, had been treated prophylactically in the past.   





































Values are medians (range), proportions (%) or number(%), 
*Data are not available 
 1972 1978 1985 1992 2001 
Severe hemophilia      
      
 prophylaxis      
  children (0-16 yrs) 22/65 (34) 41/91 (45) 69/111 (62) 64/92 (70) 112/130 (86) 
  adolescents (17-25 yrs) 12/39 (31) 27/54 (50) 43/72 (60) -- 38/42 (90) 
  adults (above 25 yrs) 8/57 (14) 28/99 (28) 71/201 (35) 119/232 (51) 134/248(54) 
      
age at first prophylaxis --*  8 (0-15) 5 (1-15) -- 2 (0-11) 
      
 home treatment 7 (4) 72 (29) 259 (67) 286 (74) 346 (82) 
      
Moderate hemophilia      
      
 prophylaxis      
  children (0-16 yrs) 6/41 (15) 9/41 (22) 7/59 (12) 7/41 (17) 7/46 (15) 
  adolescents (17-25 yrs) 4/14 (29) 7/26 (27) 1/19 (5) -- 4/23 (17) 
  adults (above 25 yrs) 1/27 (4) 4/39 (10) 10/97 (10) 11/98 (11) 10/107 (9) 
      
home treatment 2 (2) 14 (13) 39 (22) 51 (30) 57 (32) 




The median age of starting prophylactic treatment was 2 years in 2001 (range, 0-11 years), 
compared to 8 years (range, 0-15 years) in 1978 and 5 years (range, 1-15 years) in 1985.  
 
The majority of patients on prophylaxis (64%; n=195) infused clotting factor concentrate 
themselves.  The percentage of patients on home treatment had increased from 4% in 1972 to 
82% in 2001. In 2001, 88% (n=269) of patients on prophylaxis were on home treatment.     
Patients who had been treated in the year preceding the survey had used plasma-derived 
products (41%, n=300) and recombinant factor VIII or IX products (48%, n=349) equally as 
often. Among children younger than 16 years, a larger proportion solely used a recombinant 
product (78%, n=155).   
 
Outcome of treatment 
Table 3 shows effects of treatment over 30 years. Of all patients with severe hemophilia 
participating in 2001, 21 % (n=88) reported no hemorrhages in the previous year, compared 
with 36% (n=64) of patients with moderate hemophilia and 68% (n=319) of patients with 
mild hemophilia.  
Since 1972 the annual median number of symptomatic hemorrhages has gradually decreased: 
from 20 (range, 0-98 symptomatic hemorrhages) in 1972 to 5 (range, 0-51 symptomatic 
hemorrhages) in 2001 in children with severe hemophilia, whereas a similar trend was seen 
for patients with moderate hemophilia. In patients with mild hemophilia the overall median 
number of hemorrhages was zero in all 5 surveys. Hemorrhages were most frequent into 
joints. In 2001 patients with severe hemophilia had on average 3 joint bleeds (range, 0-75 
joint bleeds), compared with seven joint bleeds (range, 0-80 joint bleeds) in 1992.  A 
substantial number of hemorrhages were traumatic, especially in children (46% versus 16% 
in adult patients). 




Table 3. Outcome of treatment presented for patients with severe hemophilia and moderate hemophilia 
 
Values presented are medians (range) or percentages 
*Reported for the year previous to the questionnaire 
†Due to hemophilia in patients following full time day education   
‡Total absence in employed people between 15 and 64 yrs 
 
One or more hospital admissions during the year preceding the survey decreased from 51% of 
patients with severe hemophilia in 1972 to 22% in 2001, which still clearly exceeded the rate 
of hospitalization in the general Dutch male population, which was 5% in 2000. The median 
 1972 1978 1985 1992 2001 
Severe hemophilia 159 245 384 387 420 
      
hemorrhages (nr.per year)*        
 children ( 0-16 yrs) 20 (0-98) 20 (0-70) 10 (0-65) 10 (0-98) 5 (0-51) 
 adolescents ( 17-25 yrs) 20 (0-98) 17 (0-100) 10 (0-90) 10 (0-98) 6 (0-75) 
 adult (above 25 yrs) 14 (0-97) 15 (0-100) 10 (0-90)  10 (0-82)  7 (0-75) 
      
hospital admissions*      
   hemophilia (%) 51 38 25 22 22 
   Dutch males (%) -- -- 6 6 5 
  duration of stay (days/patient) 28 (2-252) 20 (1-180) 11 (1-100) 5 (0-330) 7 (0-89) 
      
absenteeism due to hemophilia*      
 school (days)† 30 (0-80) 15 (0-80) 4 (0-80) 2,5 (0-80) 7 (0-90) 
 work (days)‡ 15 (0-80) 20 (0-213) 7 (0-319) 8 (0-330) 5 (0-365) 
      
Moderate hemophilia      
      
hemorrhages (nr. per year)      
 children ( 0-16 yrs) 4 (0-40) 10 (0-104) 3 (0-66) 7 (33) 2 (0-57) 
 adult (above 25 yrs) 4 (0-50) 5 (0-100) 2 (0-40) 3 (0-52) 1 (0-71) 
      
hospital admissions      
 admitted (%) 51 27 23 22 15 
 duration of stay (days/patient) 17 (2-180) 10 (1-50) 7 (1-50) 5 (0-72) 6 (0-31) 
      
absenteeism due to hemophilia      
 school (days) 30 (0-80) 5(0-80) 3 (0-50) 0 (0-15) 5 (0-20) 




duration of stay in the hospital of patients with severe hemophilia decreased from 28 in 1972 
to 7 days (range, 0-89 days) in 2001, which was similar to the figure for the general Dutch 
male population. Seventy percent of the admissions were directly related to hemophilia (e.g. 
hemorrhage or orthopedic surgery). Moderate and mild hemophilia also led to 
hospitalizations in excess of the rate in the population: in both patient populations 15% had to 
be admitted in 2001. Orthopedic surgery was a frequent indication for hospitalization, which 
occurred in 26% (n=107) of patients with severe hemophilia, in 17% of patients with 
moderate hemophilia and in 13% of patients with mild hemophilia in a 5-year period 
preceding the survey. In patients with mild hemophilia, 50% of orthopedic surgery was 
related to hemophilia, for patients with moderate and severe hemophilia this was 76% and 
92%, respectively.  
In 2001, absence from school was 7 days (range, 0-90 days) among the 121 patients (29%) 
with severe hemophilia who participated in full-time education, of which 4 days were due to 
hemophilia, in patients with moderate hemophilia this was 5 days, of which 2 days were due 
to hemophilia. The median number of days that patients with mild hemophilia were absent 
from school was 3 days (range, 0-40 days), of which 1 day was due to hemophilia. Absence 
from work for 157 patients with a paid job (full-time or part-time) in 2001 was on average 5 
days, ranging from 0 days to a full year. Restricting to patients working full-time the median 
number of days absent from work was 3 (range, 0-242 days, mean,10.7 days). Considering a 
total work year of 260 days, absence from work was 4.1%. In the Dutch population this 
ranges from 5.5% (private companies) to 7.7% (civil service). In patients with moderate 
hemophilia this was 3 days (range, 0-365 days). Restriction on the capacity to perform 
regular labor among patients between 15 and 64 years with severe and moderate hemophilia 
is shown in Table 4.  
 






Table 4. Inactivity of patients aged 15 to 64 with severe and moderate hemophilia who did not follow full 













number of inactive patients (%) 24 (21) 52 (31) 
 
115 (35) 125 (36) 92 (27)† 
% inactive Dutch males 
 
9 15 23 27 23 
inactivity ratio*  
 
2.3 2.1 1.5 1.3 1.2 
median age of inactive patients 32 (16-60) 36 (19-64) 41 (19-64) 42 (20-62) 49 (17-63) 
 
 
Data presented are numbers (%), percentages or median (range) 
*The inactivity ratio was calculated as the ratio of inactivity in hemophilia patients and inactivity in Dutch males 
† χ2=3.44, p<0.05 
 
Of the  'inactive' patients, 69 patients (75%) were officially registered as fully or partially 
disabled.  Although the percentage of  'inactive' patients decreased compared to earlier 
surveys, the inactivity ratio remained constant over the last decade. In 2001 72% of patients 
with HIV infection performed a full-time or part-time paid job, compared with 51% in 1992. 
The median age of inactive patients had increased over the last 3 decades, from 32 years 
(range, 16-60 years) in 1972 to 49 years (range, 17-63 years) in 2001. Compared with the 
Dutch male population the unemployment rate was low, 2% in patients versus 2.5% in the 






Severe joint impairment was most frequently reported for the ankle, knee and elbow joints by 
patients with severe and moderate hemophilia (Table 5).  
 
Table 5. Self-reported severe joint impairment in ankle, elbow and knee joints in patients with severe and 
moderate hemophilia 
 
 Severity of hemophilia 
 severe (n=420) 
(<0.01 IU ml) 
moderate (n=176) 
(>0.05-0.4 IU ml) 
Ankle joints   
 left 74 (18) 9 (5) 
 right 76 (18) 10 (6) 
Knee joints   
 left 67 (16) 13 (7) 
 right 69 (16) 17 (10) 
Elbow joints   
 left 34 (8) 5 (3) 
 right 45 (11) 5 (3) 
   
 
None of the patients with mild hemophilia reported severe joint impairment in any of these 6 
main joints. The overall proportion of patients with severe hemophilia reporting one or more 
severely impaired joints did not change much over the years: 31% in 1972 and 1992 and 34% 
in 2001 (Table 6).  
 




Table 6. Self-reported impairment of the joints in patients with severe hemophilia 
  
Median joint score over 16 joints (min=0, max=48) and severe joint impairment in the left and right ankle, elbow and knee 
joints  
#  The median  joint score was calculated as the median over the sum of the scores of 16 joints, which have been scored 0=no 
impairment, 1=some impairment 2=some impairment with daily problems, 3=severe impairment with total loss of function,  
*Severe impairment with total loss of function reported in one or more of the six main joints 
 1972 1978 1985 1992 2001 
0-16 yrs      
median joint score (range)# 1 (0-19) 1 (0-25) 1 (0-10) 0 (0-7) 0 (0-33) 
severe joint impairment* 7/65 (11) 8/92 (9) 4/111 (4) 1/92 (1) 4/130 (3) 
      
17-25 yrs      
median joint score (range) 5 (0-16) 4 (0-25) 3 (0-19) 3 (0-12) 3 (0-13) 
severe joint impairment 9/39 (23) 12/54 (22) 11/84 (13) 12/64 (19) 8/42 (19) 
      
25-40 yrs      
median joint score (range) 10 (2-13) 9 (0-22) 8 (0-31) 7 (0-28) 5 (0-24) 
severe joint impairment 22/39 (56) 21/69 (30) 41/115 (36) 42/119 (35) 30/89 (34) 
      
above 40 yrs      
median joint score (range) 12 (4-26) 11 (3-41) 12 (0-42) 12 (0-40) 15 (0-48) 
Severe joint impairment 11/16 (69) 16/30 (53) 44/74(60) 63/113 (56) 102/159 (64) 
      
Overall      
median joint score (range) 5 (0-26) 5 (0-41) 5 (0-42) 6 (0-40) 5 (0-48) 




The same was observed for the median joint score, which was 5 in 1972 and in 2001. The 
percentage of patients reporting severe joint impairment in the age category 0 to16 years 
decreased since 1972. Although no change was observed in the percentage of patients with 
severe joint impairment in the age category 25 to 40 years, the median joint score showed a 
decrease.  In patients older than 40 years, an increase was seen between 1992 and 2001 in the 
percentage of patients with severe joint impairment and the median joint score.  
 
For patients with moderate hemophilia the median joint score remained low over 30 years: 1 
point in 1972 to 2 points in 2001 (Table 7). The percentage of patients reporting severe joint 
impairment in at least one of the main joints slightly increased between 1992 to 2001 from 
14% to 18%.  In patients with moderate hemophilia older than 40 years, an increase in the 
percentage of patients reporting severe joint impairment was observed.   
 
In the 2001 survey, 4 patients aged 0 to 16 years reported severe joint damage: all were 
treated with prophylaxis but still reported a high number of annual joint bleeds ranging from 
3 to 10. No data were available on the severity of these bleedings. None of these patients 
reported the presence of inhibitory antibodies.  In 2001, 43 % of the patients with severe 
hemophilia reporting severe joint impairment had one joint with total loss of function, 6% 
(n=8) reported a total loss of function in all six joints. The mean number of reported joints 
with severe impairment did not change over the years (data not shown).   
 




Table 7. Self-reported impairment of the joints in patients with moderate hemophilia 
 
Median joint score over 16 joints (min=0, max=48) and severe joint impairment in the left and right ankle, elbow and knee 
joints.  
#  The median  joint score was calculated as the median over the sum of the scores of 16 joints, which have been scored 0=no 
impairment, 1=some impairment 2=some impairment with daily problems, 3=severe impairment with total loss of function,  
*Severe impairment with total loss of function reported in one or more of the six main joints  
 1972 1978 1985 1992 2001 
      
0-16      
median joint score# (range) 0 (0-10) 0 (0-6) 0 (0-14) 0 (0-8) 0 (0-7) 
severe joint impairment*  5/42 (12) 2/41 (5) 1/59 (2) -- 1/46 (2) 
      
17-25      
median joint score (range) 2 (0-9) 1 (0-7) 1 (0-8) 1 (1-5) 1 (0-10) 
severe joint impairment 1/14 (7.1) -- 1/22 (5) -- 1/23 (4) 
      
25-40      
median joint score (range) 5 (0-27) 7 (0-17) 3 (0-20) 3 (0-12) 4 (0-16) 
severe joint impairment 2/18 (11.1) 6/24 (25) 10/58 (17) 8/45 (18) 6/35 (17) 
      
older than 40      
median joint score (range) 4 (0-10) 3 (0-15) 5 (0-24) 6 (0-24) 5 (0-44) 
severe joint impairment 3/9 (33.3) 3/15 (20) 6/36 (17) 16/53 (30) 23/72 (32) 
      
Overall      
median joint score (range) 1 (0-27) 1 (0-17) 1 (0-24) 2 (0-24) 2 (0-44) 





Of all patients with severe hemophilia, 22 % did not report impairment of any of the main 
joints in 2001 compared to 19% in 1992 (Table 8).  
 
Table 8. Absence of joint impairment in patients with severe hemophilia in the left and right ankle, elbow 
and knee.  
 
 1972 1978 1985 1992 2001 
Severe hemophilia      
0-16 yrs 26 (40) 40 (44) 53 (48) 56 (61) 76 (59) 
17-25 yrs 2 (5) 5 (9) 7 (8) 9 (14) 7(17) 
25-40 yrs -- 2 (3) 3 (3) 2 (2) 7(8) 
above 40 yrs  -- 3 (4) 1 (1) 4 (3) 
      
Overall 28 (18) 47 (19) 66 (17) 74 (19) 94 (22) 
      
Moderate hemophilia      
0-16 23 (55) 28 (68) 42 (71) 29 (71) 37 (80) 
17-25 5 (36) 13 (50) 9 (41) 17 (50) 11 (48) 
25-40 2 (11) 3 (13) 14 (24) 14 (31) 13 (37) 
older than 40 3 (33) 5 (33) 11 (31) 15 (28) 17 (24) 
 
 
The absence of joint impairment was related to age, it was reported by 59% of patients aged 
0-16, 17% of those aged between 17 and 25 years, and 3% of patients with severe hemophilia 
older than years old. In 3 decades the percentage of patients that reported no joint damage in 
the age category 0 to16 years increased from 40% to 59%, and in the age category 17 to 25 
years from 5% to 17%.  
 




Side effects of treatment 
 The presence of neutralizing antibodies to factor VIII or IX (inhibitors), either in the present 
or in the past, was reported by 13% (52/420) of patients with severe hemophilia (14% or 
51/388 in 1992), by 7% of patients with moderate hemophilia, and by 5% of patients with 
mild hemophilia (Table 9). Of these patients, 86 (96%) had hemophilia A.  
 
Table 9. Complications of hemophilia treatment 
 1972 1978 1985 1992 2001 
      
 inhibitory antibodies*       
 cumulative incidence   31/384 51/388 52/420 
   current  -- -- 19 (5)  29 (7)  15 (4)  
   past  -- -- 12 (3)  22 (6)  37 (9) 
      
HIV infection† -- -- 36 (4) 55 (8) 29 (5) 
      
 hepatitis C‡      
  current infection -- -- -- -- 344 (45) 
  past infection -- -- -- -- 97 (13) 
      
Values reported are number(%) 
*Reported for patients with severe hemophilia  
†Reported for patients treated with clotting factor before 1985 
‡Reported for patients treated with clotting factor before 1992 
 
In 2001, 29 patients (5%) treated before 1985 were HIV positive, of which 25 patients were 
also infected with HCV.  In 1992, 55 (8%) patients were HIV positive. In 2001, 344 patients 
(44%) reported a current infection with HCV, whereas 97 patients (13%) had been infected in 
the past but have cleared the virus naturally or through treatment. As no specific items 
regarding this subject were included in the questionnaire we were not able to make a 






In this repeated cross-sectional study, we studied the medical and social consequences of 3 
decades of hemophilia treatment in the Netherlands. We observed a steady decrease in the 
annual number of hemorrhages, hospital admissions, duration of stay in hospital and days 
absent from school or work. Changes in treatment are reflected by an increase in the use of 
prophylaxis, especially in children.  Despite intensified treatment, limited improvement was 
observed in self-reported impairment of joint function in patients older than 16 years. In the 
youngest patients a slight improvement was reported. 
 
Our study offers a unique overview of the health status of hemophilia patients over a 
prolonged period of time. No other nationwide studies over such a long period of time are 
available. The estimated prevalence of hemophilia at birth is 20.3 per 100.000 male 
inhabitants23. With 7.91 million men in the Netherlands the estimated total number of 
hemophilia patients in the Netherlands is 1606.  We reached 1567 patients with hemophilia 
and 70% participated in our study.  As the non responders appeared not to differ from the 
responding patients in severity and type of hemophilia and were only slightly younger (33 vs. 
36 years) we feel confident to generalize our findings to the total population of hemophilia 
patients in the Netherlands.  
Self-reported data may be less objective compared with medical records or laboratory data 
but offer an important insight in the view of patients of their own situation. Because patients 
with hemophilia, especially patients with severe hemophilia, are confronted with their disease 
on a daily basis and are well informed about their disease, we assume data on treatment and 
side effects of treatment are trustworthy. To rule out error in information on type and severity 
of hemophilia, we contacted the treating physicians.  
 




Between 1972 and 2001 the number of patients participating in the Hemophilia in the 
Netherlands project has doubled, which may be explained by the growth of the Dutch 
population and the registration of patients with hemophilia in treatment centers. Previously 
patients with severe hemophilia could be treated in hospitals all over the country.  Since 2001 
all patients with hemophilia need to be registered in one of the treatment centers.  
 
Hemophilia treatment has intensified over the last three decades. We observed a marked 
increase in the use of prophylactic treatment in children, whereas in adults this was less 
pronounced. In 2001, 85% of all children with severe hemophilia and over half of the adult 
patients with severe hemophilia received prophylactic treatment. This increase is likely to 
have contributed to the decrease of the annual number of total hemorrhages. If only joint 
bleeds were taken into consideration, a lower number was observed in 2001 compared to 
1992, which is in line with the findings of a single center study8. Although evolution to a 
more intense treatment regimen has resulted in a decrease of hospitalization, the percentage 
of patients with hemophilia annually admitted to hospital has still increased 3-fold compared 
to the Dutch male population. However, the number of days spent in hospital has decreased 
substantially from 28 to 7 days and is now equal to the mean duration of stay in hospital for 
all who are admitted. In our population, hospital admission occurred frequently in patients 
with mild and moderate hemophilia, which can be explained by the policy to admit patients 
with hemophilia for small operations or for observation after falls.   
 
As we also observed in the 1991 survey, there was no further improvement in perceived joint 
impairment compared to the earlier surveys covering the period 1972 to 1985.  A previous 
study presenting joint pathology by radiological assessments showed a clear improvement of 




further improve due to different appreciations of signs and symptoms over time. Remarkably, 
even among patients under age 25 with severe hemophilia, 7% reported at least one joint with 
complete loss of function in the latest survey. The discrepancy between radiological 
assessments and our findings will be subject of future study. Some patients with moderate 
hemophilia reported severe joint impairment. Although our measure for joint impairment was 
self-reported and subjective, we may conclude from this that the goal of prophylactic therapy, 
which is aimed at a trough level of 1%, may not be ambitious enough.  
 
We observed a cumulative incidence of inhibitors of 13% in patients with severe hemophilia, 
which is similar to other studies of previously treated patients24 . Since 1985 this figure has 
stayed constant. The prevalence of HIV seropositivity has declined further, due to deaths and 
an increasing number of patients born after plasma products became safe. The positive effects 
of highly active antiretroviral therapy (HAART) in 1996 for HIV positive patients were 
observed through an improvement of participation in labor since 1992. About 40% of 
hemophilia patients treated with plasma-derived products before 1992 were infected with 
hepatitis C. 
 
The number of days patients were absent from school or work due to hemophilia has 
decreased over the years. Similar figures for absence from work were shown by Szucs et al in 
199825.   Remarkably, the percentage of absence from work in men with severe hemophilia 
working full-time was lower than in the Dutch male population in 2001. An improvement is 
also seen through a decrease in the percentage of inactive patients since 1992. This is in line 
with the Dutch male population. The inactivity ratio has become close to 1, from which we 
can conclude that patients with severe and moderate hemophilia participate as actively in the 
workforce as other men. These developments show that although a large number of adult 




patients are limited in daily activities due to joint problems or viral infections, hemophilia has 
nowadays only a minimal influence on social participation.  
 
It should be taken into consideration that the focus on the use of prophylactic treatment in the 
Netherlands has lead to a 260% increased annual clotting factor consumption over the last 
three decades. Mean clotting factor consumption for both patients on prophylaxis and on 
demand treatment increased from 610 IU kg-1 year-1 in the 1970s to 1578 IU kg-1 year-1 in the 
1990s8. Clotting products have not become cheaper, which implies a larger increase in costs, 
which, however has been accompanied by direct and indirect gains (e.g., a decrease in 
absence from work and increased employment rates).  
 
In conclusion our study shows that the treatment of patients with severe hemophilia in the 
Netherlands has focused on the use of prophylactic treatment, especially in children. This has 
resulted in an improvement of the medical and social situation of patients. Although the 
current situation of Dutch hemophilia patients proves to be good, more improvements are 
possible. A remarkable finding was that the prevalence of perceived joint impairments among 
young patients did not show the decrease we had expected. 
 
Acknowledgements 
The authors wish to thank the Netherlands Hemophilia Society and treating physicians from 
all 15 Dutch hemophilia treatment centres that made recruitment of patients possible. We 







1.  Ahlberg A: Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and 
other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965;Suppl-
132. 
2.  Rosendaal FR, Smit C, Briët E: Hemophilia treatment in historical perspective: a review of 
medical and social developments. Ann Hematol 1991;62:5-15. 
3.  Mannucci PM, Tuddenham EG: The hemophilias--from royal genes to gene therapy. N Engl J 
Med 2001;344:1773-1779. 
4.  Larsson SA: Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985;59:593-
602. 
5.  Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E: Mortality in patients with 
hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 
1995;123:823-827. 
6.  Tusell J, Perez-Bianco R: Prophylaxis in developed and in emerging countries. Haemophilia 
2002;8:183-188. 
7.  van Creveld S: Prophylaxis of joint hemorrhages in hemophilia. Acta haemat 1971;45:120-127. 
8.  Fischer K, Van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, van 
den Berg HM: Changes in treatment strategies for severe haemophilia over the last 3 decades: 
effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-452. 
9.  Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PLF, Gringeri A, 
Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, 
Schramm W, Shapiro A, van den Berg HM, Hart C: Consensus perspectives on prophylactic 
therapy for haemophilia: summary statement. Haemophilia 2003;9:1-4. 
10.  Astermark J: When to start and when to stop primary prophylaxis in patients with severe 
haemophilia. Haemophilia 2003;9:32-36. 
11.  Shapiro AD: A global view on prophylaxis: possibilities and consequences. Haemophilia 
2003;9:10-17. 
12.  Gringeri A: Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 
2003;9:38-42. 
13.  Manco-Johnson MJ, Blanchette VS: North American prophylaxis studies for persons with severe 
haemophilia: background, rationale and design. Haemophilia 2003;9:44-48. 
14.  Mannucci PM: Clinical-Evaluation of Viral Safety of Coagulation Factor-VIII and Factor-IX 
Concentrates. Vox Sanguinis 1993;64:197-203. 
15.  Mauser-Bunschoten EP, Roosendaal G, van den Berg HM: Product choice and haemophilia 
treatment in the Netherlands. Haemophilia 2001;7:96-98. 
16.  Zwart-van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW: The uptake of 
recombinant Factor VIII in the Netherlands. Br J Haematol 2002;119:332-341. 




17.  Paisley S, Wight J, Currie E, Knight C: The management of inhibitors in haemophilia A: 
introduction and systematic review of current practice. Haemophilia 2003;9:405-417. 
18.  Triemstra AHM, Smit C, Van der Ploeg HM, Briët E, Rosendaal FR: Two decades of 
haemophilia treatment in the Netherlands, 1972-'92. Haemophilia 1995;1:165-171. 
19.  Smit C, Rosendaal FR, Varekamp I, Bröcker-Vriends A, Van Dijck H, Suurmeijer TP, Briët E: 
Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. BMJ 
1989;298:235-238. 
20.  Central Bureau of Statistics Netherlands. StatLine databank. 
http://www.cbs.nl/nl/cijfers/statline/index.htm Accessed 2003 
21.  Werkgroep Hemofilie Onderzoek (1979): Hemofilie in Nederland-2: resultaten van een in 1978 
gehouden enquete (Hemophilia in the Netherlands 2: report of a survey in 1978) University 
Hospital Leiden , 1979. 
22.  Rosendaal FR, Smit C, Varekamp I, Bröcker-Vriends AHJT, Vandijck H, Suurmeijer TPBM, 
Vandenbroucke JP, Briët E: Modern Hemophilia Treatment - Medical Improvements and Quality-
Of-Life. Journal of Internal Medicine 1990;228:633-640. 
23.  Rosendaal FR, Briët E: The Increasing Prevalence of Hemophilia. Thrombosis and Haemostasis 
1990;63:145. 
24.  Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, Van 
der Meer J, Smit C, Strengers PFW, Briët E: A Sudden Increase in Factor-VIII Inhibitor 
Development in Multitransfused Hemophilia A Patients in the Netherlands. Blood 1993;81:2180-
2186. 
25.  Szucs TD, Offner A, Kroner B, Giangrande P, Berntorp E, Schramm W: Resource utilisation in 
haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of 















Iris Plug, Johanna G. van der Bom, Marjolein Peters, Eveline P. Mauser-Bunschoten, Arja de 






















Hemophilia is a hereditary clotting disorder characterized by bleeding occurring 
spontaneously (severe hemophilia) or after trauma and medical interventions (moderate and 
mild hemophilia). Since the introduction of replacement therapy in the 1960s medical and 
social circumstances have gradually improved. We compared social functioning and health 
related quality of life between hemophilia patients and the general male population.  
All Dutch patients with hemophilia between 15 and 64 years were surveyed by a mail 
questionnaire. We gathered data on severity and type of hemophilia, viral infections, 
education, and employment. The Short Form 36 (SF-36) was used to assess Health Related 
Quality of life. Social functioning of patients born before (now 31-64 years of age) and after 
(now 15-30 years of age) the introduction of prophylactic treatment (around 1970) was 
compared to the general age-adjusted male population.  
Of 1567 patients who were sent a questionnaire, 1066 returned it, of whom 733 were men 
between 15 and 64 years. Patients with severe hemophilia participated less in full time work 
compared to the general population; this difference with the general population was largest 
for the older patients. Occupational disability was reported by 35% of patients with severe 
hemophilia between 30 and 64 years, compared to 9% in the general population. Health-
related quality of life of patients with severe hemophilia between 30 and 64 years was lower 
than of the general population on all domains. The differences with the general population in 
health related quality of life were least pronounced for patients between 15 and 30 years.  
Despite major improvements in treatment during the last decades patients with hemophilia are 
still less involved in full time paid work and suffer more from occupational disability than 





Hemophilia is a X-linked hereditary bleeding disorder caused by deficiency of coagulation 
factor VIII (hemophilia A) or factor IX (hemophilia B). Severe forms are characterized by 
major bleeding occurring spontaneously or after minor trauma. Repeated bleeding into joints 
may result in orthopedic problems due to hemophilic arthritis1. 
 
Since its introduction in the late 1960s replacement therapy with clotting factor VIII or IX has 
improved the medical and social situation of patients with hemophilia2,3. This is illustrated by 
considerable decreases in the annual number of hemorrhages, hospital stays and absence from 
work or school 4. Furthermore, since the 1970s an increasing number of patients have 
successfully been treated prophylactically.  In the 1980s many patients became infected with 
the Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV). Since 1985, 
products have been safe for HIV and since 1992 also for the transmission of HCV.  
 
Our aim was to examine whether social functioning and quality of life of today's hemophilia 
patients differ from that of men without hemophilia.  
 
Material and methods 
Participants  
A nationwide postal survey among all known patients with hemophilia, the Hemophilia in the 
Netherlands-5 study4, was conducted in the Netherlands in 2001, following four previous 
surveys dating back to 1972. Details on this survey have been described previously4.  Patients 
included were listed with the Netherlands Hemophilia Society, with the hemophilia treatment 
centers, or were known from updated mailing lists from previous surveys. The response to the 
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Hemophilia in the Netherlands-5 study was 70% (1066 out of 1519). For the present study we 
included all 733 participants who were between 15 and 64 years of age.  
 
Assessments   
A pre-structured questionnaire was part of a series of questionnaires that were used between 
1972 and 2001 and included many items that were identical. We implemented the Short-
Form-36 (SF-36) questionnaire that measures Health-related quality of life. The SF-36 is a 
36-item questionnaire that measures eight parameters of perceived health status: physical 
functioning, social functioning, role limitations due to physical problems, role limitations due 
to emotional problems, mental health, pain, vitality and general health perception. Viral 
status, treatment modalities, educational levels and annual numbers of hemorrhages were 
assessed through self-reported data.  The self reported type and severity of hemophilia were 
verified with data from the treatment centers. Data on the absence from school or work 
referred to the year that preceded the survey (2000). Data on employment, occupational 
disability and employment levels were compared to national figures on the general male 
population that were provided by the Central Bureau of Statistics Netherlands (CBS)5.  
All occupations reported by participants were scored according to the Standard Occupational 
Classification (SBC) published by the CBS6. According to this classification, occupations are 
distinguished through the level of the needed abilities to perform the occupation. The 
classification differentiates between the following employment levels:  elementary level, low 
level, moderate level, high level and academic level. The levels of employment are in line 
with educational level e.g. to perform a job at the elementary level primary education is 
needed and to perform a job at the high level secondary school at the highest level or college 
is needed. The jobs at the elementary level and the low level were considered to be blue-collar 




Occupational disability according to Dutch law 
The Netherlands has an extensive social security system, which includes several social 
insurance schemes which offer protection against the risk of loss of income and exceptional 
expenditure due to old age, death, illness, disablement or unemployment.  
The Occupational Disability Insurance Act (WAO) provides insurance against the financial 
consequences of long-term incapacity to work. Under the WAO people are entitled to benefits 
if they have been disabled for more than 52 weeks. According to the Dutch system 
occupational disability is defined as not being able to perform normal labour due to disease or 
a deficiency. In our study occupational disability status was self-reported.  
 
Data analyses 
We categorized the patients according to whether they were born before (now aged 30-64 
years) or after (now aged 15 to 30 years) the introduction of prophylaxis in the Netherlands. 
As the clinical characteristics of hemophilia A and hemophilia B do not differ we present 
combined results for hemophilia A and B. The severity of hemophilia was classified 
according to residual percentage of factor VIII or IX clotting activity: severe (<0.01 IU/ml), 
moderate (0.01-0.05 IU/ml) or mild (>0.05-0.40 IU/ml). The inactivity ratio was calculated as 
the ratio of inactivity in the study population and inactivity in Dutch men. Patients that did not 
have a paid job were defined as inactive. The outcome values of the SF-36 were compared to 
age-specific reference data for the Netherlands7. In the analyses on health-related quality of 
life (HRQol) we only included patients without missing values on any of the domains.  We 
calculated mean values and differences for all health-related quality of life scales; in addition 
we calculated differences adjusted for age. 




A total of 1066 patients with hemophilia A or B participated in our study (response 74%), and 
of all patients who responded 733 were aged between 16 and 64 years and therefore eligible 
for the current analyses. Of 6 patients information on employment was missing; they were 
excluded from the analysis.  
 
Table 1. Personal characteristics of participants according to age and severity of 
hemophilia 




Born before introduction 
prophylaxis  (30-64 yrs) 
N=200 N=337 
   
Type of hemophilia    
 Hemophilia A 170 (85) 297 (88) 
 Hemophilia B 30 (15) 40 (12) 
   
Treatment modalities   
 Prophylactic  105 (53) 8 (2) 
 On demand  28 (14) 271 (80) 
 Combination 60 (30) 22 (7) 
   
Viral infections   
 Hepatitis C positive 149 (75) 108 (32) 
 HIV positive 17 (9) 6 (2) 
   
Born after introduction 
prophylaxis  (15-30 yrs) 
N=83 N=107 
   
Type of hemophilia    
 Hemophilia A 69 (83) 92 (86) 
 Hemophilia B 14 (17) 15 (14) 
   
Treatment modalities   
 Prophylactic  68 (82) 8 (8) 
 On demand  8 (10) 76 (71) 
 Combination 7 (8) 18 (17) 
   
Viral infections   
 Hepatitis C positive 41 (49) 18 (17) 
 HIV positive 6 (7) 0 
 




Table 1 shows the characteristics of patients with severe hemophilia (n=283) and patients 
with moderate and mild hemophilia (n=444) according to the two age groups. Patients born 
after the introduction of prophylaxis more often used prophylactic treatment than patients 
before the introduction of prophylaxis (82 vs. 53%).  The prevalence of HIV and hepatitis C 
positivity was higher in severe hemophilia than in moderate and mild hemophilia both in men 
born before the introduction of prophylaxis (difference =43%, 95% Confidence Interval (CI) 
35-50) and born after the introduction of prophylaxis (difference= 33%, CI 20-46).  
 
Employment status  
Table 2 shows the employment status of hemophilia patients compared to the general 
population, according to whether patients were born before or after the introduction of 
prophylactic treatment.   
The participation in full time paid work for patients with mild and moderate hemophilia was 
similar to the general population in both age groups (71% vs. 73% in those aged between 30 
and 65 years, and 46% vs 52% in those aged between 15 and 30 years). Patients with severe 
hemophilia participated less in full-time paid work than the general male population, 50% vs. 
73% (difference=23%, CI 17-31).  In young patients (15-30 yrs) with severe hemophilia the 
difference with the general population was 19% (33% vs. 52%).  One third of the younger 
patients participated in full time education (n=86, 30%).   
 
Patients with severe hemophilia slightly more often were part-time employed than men of the 
general population, especially in the oldest age category. In both age groups unemployment 
occurred less often than in the general population: inactive patients were mainly legally 
disabled. Overall in 2001 27% of patients (severe and moderate hemophilia) were inactive 
compared to 23% in the Dutch male population, resulting in an inactivity ratio of 1.2.  
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Born before introduction 
prophylaxis (30-64 years) 
200 337 3.906.000 
    
Full time education  0 0 ?  
Part time education 11 (60)* 15 (5)† ?  
Full-time work 99 (50) 240 (71) 2860 (73) 
Part-time work 35 (18) 26 (8) 378 (10) 
Unemployed 2 (1) 6 (2) (2.3) 
Occupational disability 69 (35)** 52 (15) 282 (9) 
Retired  7 (4) 12 (4)  
    
Born after introduction 
prophylaxis (15-30 yrs) 
83 107 1.527.000 
    
Full time education‡  37 (45) 49 (46) ?  
Part time education• 6 (7) 14 (13) ?  
Full-time work 27 (33) 47 (44) 792  (52) 
Part-time work 21 (25) 17 (16) 371 (24) 
Unemployed 1 (1) 3 (3) (5.4)  
Occupational disability 4 (5) 2 (2) 46.9 (2) 
Data presented are numbers or number (percentage)  
*8 patients were involved in either full-time or part-time work, **15 patients were both disabled and involved in 
either full-time or part-time work, † 13 patients were also involved in full-time or part-time work and 1 patients 
was disabled, ‡ 12 patients with severe hemophilia were also involved in part-time work and 13 patients with 
moderate or mild hemophilia, •5 patients with severe hemophilia and 12 with moderate/mild hemophilia 
hemophilia were involved in either full-time or part-time work 
 
Table 3 shows the level of employment according to severity of hemophilia and among the 
general population. Fewer patients were employed in blue-collar work than in the general 
population (24%), both for patients with severe hemophilia (13%) and for patients with mild 
and moderate hemophilia (20%). The employment in managerial or academic positions 





Table 3.Employment level according to severity 











Elementary level 4 5 6 
    
Lower level 13 20 24 
    
Moderate level 36 39 38 
    
High level 29 25 21 
    
Academic level 12 7 9 
    
Unknown 5 3 2 
Data presented are percentages  
Only patients included who have a full-time or part-time paid job 
*All reported professions were scored according to a standard classification in which the employment levels resemble 
educational levels.  
 
 
Limitations in work 
Legal occupational disability was reported by 35% (69/200) of patients with severe 
hemophilia between 30 and 64 years, compared to 9% in the general population. In patients 
with mild and moderate hemophilia the difference in occupational disability with the general 
population was 6% for patients between 30 and 64 years. The proportion of young patients 
with moderate and mild hemophilia who were disabled was similar to that in the general 
population. A substantial number of the employed patients with severe hemophilia reported to 
experience restrictions in performing their job due to hemophilia (71 out of 181, 39%). In 
patients with mild or moderate hemophilia this was 19%. These restrictions consisted of pain 
and frequent absence from work.  
 
Social functioning of patients with hemophilia 
 
73 
Health-related quality of life 
A total of 623 patients completed the SF-36 of whom 532 patients were eligible to work. 
Table 4 shows health-related quality of life of patients involved in a paid job, either full-time 
or part-time (n=422), and of patients who were not employed (n=110).  
 
Table 4. Health-related Quality of life in relation to employment.  
 Employment 








Difference (95CI) Adjusted for age (95CI) 
Physical 
functioning 
81.6 (24.0) 47.8 (31.9) 33.8 (28.3-39.2) 28.3 (22.9-33.6) 
Social 
functioning 
87.1 (20.2) 63.0 (26.9) 24.1 (19.5-28.7) 21.6 (16.9-26.3) 
Role-Physical 79.6 (35.5) 39.8 (43.0) 39.8 (32.0-47.7) 37.3 (29.3-45.4) 
Role-Emotional 88.2 (29.3) 59.4 (45.2) 28.8 (21.9-35.8) 26.5 (19.3-33.7) 
Mental health 78.9 (15.9) 67.1 (20.9) 11.8 (8.2-15.4) 10.6 (6.9-14.3) 
Vitality 69.1 (18.7) 54.7 (20.1) 14.4 (10.4-18.4) 13.2 (9.0-17.3) 
Bodily pain 81.5 (21.3) 61.0 (29.0) 20.4 (15.6-25.3) 19.4 (14.4-24.4) 
General health 70.3 (20.8) 50.7 (26.1) 19.6 (15.0-24.3) 18.0 (13.3-22.8) 
Only patients included who were eligible to work (not involved in full-time education or retired). 
 
Differences between the employed and unemployed patients were largest in the domain of 
physical functioning (28 points CI 23-34), role limitations due to physical problems (37 points 
CI 29-45) and role limitations due to emotional problems (27 points CI 19-34). Employed 




patients. Patients with severe hemophilia aged between 30 and 64 years scored lower on all 
scales of the SF-36 except mental health than the general population (Table 5a).  
 






Born before introduction of 
prophylaxis  (30-64 years) 
Mean (sd) Mean (sd) Mean (sd) 
Physical functioning 45.9 (28.5) 83.1 (23.8) 84.0 (19.6) 
Social functioning 72.5 (25.7) 83.5 (23.8) 83.5 (22.1) 
Role-Physical 49.5 (43.8) 78.4 (37.5) 74.5 (36.8) 
Role-Emotional 67.4 (42.9) 85.2 (33.0) 81.6 (33.2) 
Mental health 73.4 (19.1) 76.6 (18.5) 75.6 (18.5) 
Vitality 61.4 (20.7) 66.6 (21.1) 68.6 (20.2) 
Bodily pain 64.5 (24.3) 82.5 (23.5) 71.8 (24.1) 
General health perception 56.8 (23.5) 68.3 (23.3) 69.7 (20.6) 
 






Born after introduction of 
prophylaxis  (15-30 years) 
Mean (sd) Mean (sd) Mean (sd) 
Physical functioning 82.2 (21.4) 94.0 (12.9) 93.1 (11.8) 
Social functioning 87.6 (20.2) 91.4 (17.5) 87.8 (19.1) 
Role-Physical 73.0 (38.0) 90.4 (24.6) 86.4 (27.6) 
Role-Emotional 86.6 (29.0) 94.9 (20.3) 85.4 (30.0) 
Mental health 79.9 (14.0) 80.1 (14.5) 78.7 (15.2) 
Vitality 71.9 (15.1) 72.2 (15.6) 70.7 (16.4) 
Bodily pain 76.9 (22.9) 88.7 (18.9) 80.9 (19.4) 
General health 69.9 (22.2) 76.2 (18.3) 78.4 (17.3) 
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Patients with severe hemophilia between 15 and 30 years scored lower on physical 
functioning, role limitations due to physical functioning, bodily pain and general health than 
the general population, but not on role limitations due to emotional functioning, mental health 
and vitality (table 6).  
Patients with moderate and mild hemophilia between 30 and 64 years scored higher on role 
limitations due to physical limitations, role limitations due to physical problems, mental 
health and bodily pain than men from general population. Younger patients with moderate 
and mild hemophilia scored higher or had a similar score on all scales, but scored lower on 
general health.  .  
 
Discussion  
When compared to the general population, patients with severe hemophilia participate less in 
full time work; they suffer more often from occupational disability, and mainly are employed 
at high job levels. Patients with moderate and mild hemophilia differ only slightly or not from 
their peers.  
 
Our study offers an overview of the occupational status of Dutch hemophilia patients in 2001. 
The estimated prevalence of hemophilia is 20.3 per 100.000 inhabitants 8. With 7.91 million 
men in the Netherlands the estimated total number of hemophilia patients in the Netherlands 
is 1606. We reached 1567 patients with hemophilia, and 70% participated in our study.  As 
the non-responders appeared not to differ from the responding patients in severity and type of 
hemophilia and were only slightly younger (33 vs. 36 years) we feel confident to state that our 
findings validly describe the situation of hemophilia patients in the Netherlands. Our data 
were compared to information from the Central Bureau of Statistics (CBS) providing 




were assessed using self-reported questionnaires. However misclassification may have 
influenced our findings on occupational disability; the CBS gathered these data through 
disability registries while we collected self-reported data.  
 
In 1985, we performed a similar study examining prospects of hemophilia patients in the 
labour market, and found an overall percentage of employment (either full-time or part-time) 
of 58% in patients between 15 and 65 years9. In the present study, overall employment was 
70%. Apparently since 1985 the social situation of hemophilia patients has improved. 
However, secular trends have also occurred in the general population, and therefore we 
calculated the inactivity ratio, which was 1.5 in 1985 compared to 1.2 in 2001 4.  A study 
from Great-Britain reported that 65% of all patients with severe hemophilia were full-time 
employed10.  
Despite important improvements, employment figures among young patients were slightly 
lower than among the general population. One explanation may reside in the fact that 
hemophilia patients more often followed full time education. Additionally, hepatitis C 
infections may have affected employment status, especially among patients with severe 
hemophilia. Although the period between infection and clinical problems is long, some young 
patients may already be faced with physical problems such as liver cirrhosis. And, treatment 
of hepatitis C may cause serious side effects, which may also influence participation in 
"normal" social life.  
 
Our findings confirm those of earlier studies reporting a higher educational level of patients 
with hemophilia11. A survey performed in 1985 showed that 72% of patients with hemophilia 
were involved in white collar jobs compared to 57% of the general population9. This 
transition towards the "white collar" jobs can be explained by the fact that blue- collar jobs 
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may not be suitable for patients with hemophilia, in which case it is not so much that 
hemophilia patients are more often employed in high level jobs, but that they are less often 
employed in blue collar jobs. There are several aspects that hemophilia patients have to take 
into account of which the risk of bleeding due to daily activities in work is probably the most 
important. Another aspect influencing the choice of work may be the presence of hemophilic 
arthropathy resulting from repetitive bleeding into joints. Arthropathy has a negative effect on 
labor force participation 12. Of course patients born before the introduction of prophylaxis 
may have developed joint damage earlier in their lives. It has been shown that prophylaxis 
started later in life does not halt the progression of arthropathy13. 
 
The association between employment and health related quality of life should be interpreted 
with caution. Many factors may influence health related quality of life, such as viral infections 
and the presence of arthropathy. Health-related quality of life of patients with severe 
hemophilia born before the introduction of prophylactic treatment in the Netherlands was 
lower than that of the general population. In young patients quality of life seems to be similar 
to the general population.  
 
Despite major improvements in treatment during the last decades patients with hemophilia are 
still less involved in full time paid work and suffer more from occupational disability than 
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Summary 
Hepatitis C is a major co-morbidity among patients with haemophilia who received 
inadequately or non-virus inactivated clotting factor concentrates before 1992. The 
objectives of this study were to investigate the prevalence of hepatitis C and the use of 
antiviral therapies during the last decade among patients with haemophilia in the 
Netherlands.  
We performed a cross-sectional study and a questionnaire was sent to all 1519 patients 
known with haemophilia in the Netherlands between 2001 and 2002. The study population 
for the present study consisted of 771 patients who had received clotting factor products 
before 1992 of whom 638 reported their hepatitis C status. 
In total 441 of the 638 (68%) patients ever had a positive test for hepatitis C virus (HCV); 
344 patients (54%) had a current infection, and 97 (15%) had cleared the virus. Among 344 
patients currently HCV infected, 111 (32%) had received treatment for hepatitis C, while 
34% (33/97) of patients with an infection in the past had been treated for hepatitis C.  
In 2002 the prevalence of hepatitis C among patients with haemophilia who received clotting 
factor products before 1992 was 54%. The majority of patients with a current HCV infection 





Haemophilia is an X-linked bleeding disorder caused by a partial or complete lack of clotting 
factor activity: factor VIII in haemophilia A and factor IX in haemophilia B. Since the 1960s 
haemophilia patients have received intravenous factor VIII and IX replacement therapy1. In 
the following years it became apparent that viruses like Human Immunodeficiency Virus 
(HIV) and hepatitis C virus (HCV), formerly known as non-A non-B hepatitis, were 
transmitted due to transfusion of infected plasma products2,3.  Patients treated with large pool 
products were infected with HCV in 98%, whereas patients treated with cryoprecipitate were 
infected in 66% of the cases4. In the early 1990s, methods were developed to adequately 
inactivate HCV and subsequently donor screening for HCV was introduced, resulting in HCV 
safe clotting products4-6.   
Once infected, about 10-20% of the patients are able to clear the virus spontaneously, while 
the others develop a chronic carrier state7-9.  Untreated HCV infection may progress to liver 
fibrosis, cirrhosis or hepatocellular carcinoma10,11.  Liver disease caused by HCV is now 
recognized as an important cause of morbidity in haemophilia patients12. Treatment for non-
A non-B hepatitis became available in 198613,14.  Today pegylated interferon (Peg-IFN) in 
combination with ribavirin is the most effective therapy for hepatitis C15.Success of therapy 
is mainly dependent on genotype and viral load16. Antiviral drugs cause side effects, like 
anaemia, neutropenia, depression and flu-like symptoms in the majority of the patients17-19.   
Little or no information is available on the current prevalence of hepatitis C and antiviral 
treatment history among patients who have received inadequately or non-virus inactivated 
clotting factor concentrates before 1992. We therefore investigated the prevalence of hepatitis 
C infection and assessed the use of antiviral therapy among patients with haemophilia in the 
Netherlands.  
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Materials and methods 
Setting 
Data for the present study were collected within the last survey of a series initiated by 
Veltkamp in 197220. Since then nationwide surveys were repeated in 1978, 1985, 1992 and in 
200121-24.  These studies aimed to assess the medical and social consequences of haemophilia 
in the Netherlands. In 2001, postal questionnaires were sent to all 1519 patients known with 
haemophilia in the Netherlands, who were either registered at the Netherlands Hemophilia 
Patients Society, at the haemophilia treatment centres or known from previous surveys. In 
this last survey items on hepatitis C were added for the first time. 
 
Data 
The study population consisted of patients who were treated with clotting factor products 
before 1992 and who reported their hepatitis C status. These patients were potentially at risk 
for HCV infection because they were treated with non-virus inactivated or inadequately 
inactivated clotting factor concentrates. Severity of haemophilia was defined by the 
percentage of factor VIII or factor IX clotting activity: severe haemophilia <1%, moderate 
haemophilia 1-5%, and mild haemophilia 5-40% clotting factor activity. Reported type and 
severity of haemophilia were verified with information from the treatment centres. In 
addition, data on haemophilia type and severity of non-responders were obtained from 
treatment centres or from the previous questionnaire performed in 1992. Haemophilia type 
and severity of 346 non-responders were similar to those in the study population. Items on 
hepatitis C and HIV were obtained from the questionnaire. Information on the hepatitis B 




To assess the validity of the self-reported items on hepatitis C, a random sample of 92 
patients (14%) was taken from the two largest participating centres verifying their reported 
hepatitis C status with information from their treating haematologist.    
 
Statistics  
Infection with HCV was defined as three possible status: never infected with HCV, HCV 
infection cleared and chronic hepatitis C. 'Never infected with HCV' was defined as negative 
for both HCV antibodies and HCV-RNA in serum. A 'cleared HCV infection' or 'infection in 
the past' was defined as positive for HCV antibodies but negative for HCV-RNA. 'Chronic 
hepatitis C' was defined as positive for both HCV antibodies and HCV-RNA. In addition, 
'ever infected with HCV' was defined as positive for HCV antibodies, regardless of the HCV 
RNA result. 
To study risk of infection according to period of treatment, a sub-analysis was performed 
comparing infection rates between patients first treated before 1985 with patients first treated 
between 1985 and 1992. Patients with incomplete treatment history were excluded for this 
sub-analysis. 
The HCV status according to type and severity of haemophilia was compared by using the 
Chi-Square test. Mean values with 95% confidence intervals of age according to severity of 
haemophilia and HCV infection status were calculated.  
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Fig. 1. Flowchart of selection of study population. 
Not tested for HCV, n=57































The response to the questionnaire was 1066 of 1519 (70%). General characteristics of the 
participants are shown in Table 1.  
 
Table 1. Patient characteristics* 
 




Age in years  41 (10-87) 





 Severity of Haemophilia 






Patients treated before 1985† 523 (82%) 
 HIV positive 28 (5%) 
Patients treated before 1992‡ 638 
 Anti HCV positive 
 HCV RNA positive 
441 (68% of tested patients) 
344 (54% of tested patients) 
* Information of patients treated before 1992 with a reported HCV test result. Values are medians (range) or numbers 
(percentage) 
† At risk for HIV infection due to not adequately or non-virus inactivated clotting factor products  
‡ At risk for HCV infection due to not adequately or non-virus inactivated clotting factor products 
 
Hepatitis C 
Patients treated with clotting products before 1992  
A total of 771 patients were at risk for HCV infection (i.e. treated before 1992); 599 were 
already treated with clotting products before 1985, 136 were treated exclusively between 1985 
and 1992, whereas 36 patients reported to have been treated before 1992 but not whether they 
were also exposed to clotting products before 1985. 638 of these 771 patients reported their 
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HCV status. Among the 133 patients at risk without a HCV test result, 68% had mild 
haemophilia.  
In the verification sample, 92% (85/92) reported their hepatitis C status correctly; 96% of 
patients with an HCV infection and 88% of patients with a cleared infection or those who 
where never infected. 
Among 638 patients treated with clotting factor products before 1992 and tested for HCV, 
441 (68%) ever had an anti-HCV positive test; 344 (54%) reported to be currently infected 
with HCV, 97 (15%) reported an infection in the past and 197 patients (31%) had never been 
infected. No infections with HCV occurred in patients who were treated after 1992 only. 
HCV infection was related to type of haemophilia; patients with haemophilia B had been 
infected more often than those with type A (84% vs. 67%, P < 0.01). Among patients at risk 
for HCV transmission, patients with severe haemophilia had the highest prevalence of 
hepatitis C (severe 65%, moderate 53%, mild 37%, P < 0.001).  
The mean age of patients differed according to severity of haemophilia and HCV status; 
patients with severe haemophilia, who were never infected, were younger (mean age 23 years, 
95% confidence interval (CI) 19-28) than both patients with severe haemophilia who cleared 
HCV (37 years, CI 33-41), and those currently infected (43 years, CI 41-45). 
 
Infection rate of HCV according to treatment period  
Although HCV inactivating steps were applied since 1985, risk of HCV infection was not 
completely eliminated. 523 of 599 patients treated before 1985 and 95 of 136 patients treated 
1985-1992 reported their HCV status. Among patients treated before 1985, 62% reported to 
be currently infected, while 17% cleared HCV. In contrast, the proportion of patients with 
chronic HCV infection was only 18%, with 7% clearing HCV and 75% never infected in 




HIV infection  
The prevalence of HIV infection among patients treated before 1985 and reporting their HIV 
status was 5% (28/523).  
 
Treatment of hepatitis C 
Among the 344 patients with a current HCV infection, 68% (233) had not been treated with 
antiviral drugs. The main reasons for refraining from therapy were shrinking from side 
effects (46%), normal liver function tests (45%) and expected low effectivity (35%). Other 
reported reasons were: doctor not convinced of benefit of treatment (19%), treatment not 
discussed by doctor (18%) and lack of time among patients (9%). Over the last decade, the 
proportion of patients having been treated is increasing (Fig. 2). 






















Fig 2. Cumulative percentage of all HCV infected patients with haemophilia treated with antiviral therapy during the last 
decade. Considering a spontaneous clearance of 15%, the maximum cumulative percentage would be 85%. 
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Treatment for HCV was completed among 128 patients and successful treatment was 
reported in 26% (33/128). Sixteen patients were currently on combination therapy of IFN and 
ribavirin. Among patients who finished therapy, 57 patients were treated with IFN 
monotherapy, 51 patients with the combination of IFN and ribavirin, while 13 patients were 
first treated with monotherapy and later retreated with combination therapy. Seven patients 
did not remember their treatment regimen.  
Patients reported side effects of antiviral therapy in 84% (121/144). Fatigue (78%), flu-like 
symptoms (73%), and depressive symptoms (46%) were most frequently reported. In 15% of 
treated patients therapy was discontinued because of side effects.  
 
Discussion 
We report on a nationwide survey on the current prevalence of hepatitis C in haemophilia 
patients. Of 771 patients at risk for HCV infection, 638 reported their hepatitis C status. Fifty 
four per cent of tested patients reported to be currently infected with HCV, of whom 32% had 
been treated with antiviral therapy. 
We performed a cross-sectional study to assess the prevalence of hepatitis C infection among 
patients with haemophilia in the Netherlands and to examine the use of antiviral treatment. 
To appreciate our findings some limitations need to be discussed. First, the response rate to 
the questionnaire was 70%, and selection bias cannot be ruled out. Non-responders to the 
questionnaire may have been less severely affected, therefore failing to see the need for a 
survey in this population. This may have led to an overestimation of the prevalence of 
hepatitis C. However, percentages of type and severity were similar in responders and non-
responders, rendering bias less likely.  
Secondly, self-reported data may be unreliable. We therefore performed a validation study, 




that, most patients with haemophilia are well informed about their disease and its 
complications21.  
In this study, 68% of all tested patients potentially exposed to insufficiently viral inactivated 
clotting factor products had ever been infected with HCV and 54% of them reported a current 
HCV infection. The prevalence of hepatitis C in this population is similar to that reported by 
others4,9,25.  As expected, the prevalence was highest among patients with severe haemophilia 
due to a higher number of exposures to clotting products than patients with mild or moderate 
disease. Haemophilia B was associated with a higher HCV infection rate (84% vs. 67%) due 
to exclusive treatment with large pool plasma products, whereas patients with haemophilia A 
were in many cases exclusively treated with small pool cryoprecipitate26. Confirming data in 
a Dutch study on 316 patients, reported HCV infection rates of 66% and 98% in patients 
exclusively treated with small pool cryoprecipitate and patients treated with large pool 
products, respectively4. In addition, the proportion of patients with severe haemophilia was 
higher among patients with haemophilia B than in those with haemophilia A (58% vs. 48%), 
with concomitant higher exposure rates to potentially unsafe clotting factor products. 
In our study, we found that the risk of HCV transmission was lower among younger patients. 
This may be explained by the lower number of exposures and the introduction of dry heat 
treatment (up to 68°C) in 1985. Although completely effective for HIV, this method of viral 
inactivation did not eliminate HCV infection risk, but resulted in a reduction of HCV load 
only27. This is also shown in our study, in which patients exclusively treated with clotting 
products between 1985 and 1992, had a lower risk of HCV infection than patients treated 
before 1985. Although this risk was decreased, HCV transmission was not eliminated. 
Finally, donor screening, pasteurisation, steam heat treatment and chemical viral inactivation 
through the combination of solvent and detergent methods were introduced on a large scale, 
eliminating transmission of HCV completely in 19926,28,29.   
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Although there has been a trend towards starting treatment of HCV infection, so far only 32% 
of the HCV infected patients reported use of antiviral therapy, with a success rate of 26%. 
The main reasons for refraining from antiviral therapy were expected low effectivity of 
therapy, normal liver function tests and expected side effects. The argument of low expected 
effectivity loses its strength as treatment with PegIFN and ribavirin results in a sustained 
response in 50- 90% in treatment naive patients dependent on viral genotype18. It has been 
suggested that refraining from therapy in case of normal liver function tests may be 
appropriate in patients with genotype 1 and 4 with normal histology at liver biopsy30. But this 
is inappropriate in patients with HCV genotype 2, 3 and 5, of whom 90% will achieve a 
sustained response.  
Fatigue, flu-like symptoms and depression were the most frequently reported adverse events 
of antiviral therapy; this is in accordance with other reports17. Depression has been a common 
indication for dose reduction or even discontinuation of therapy17,31.  Discontinuation of 
therapy due to adverse effects was reported in 15% in this study and was similar to that 
reported by others18,19,32,33.  
The reported reasons for refraining from antiviral therapy indicate that there are still 
uncertainties about long-term complications of hepatitis C and effectivity of antiviral therapy. 
Therefore, patients need to be fully informed about HCV infection, its consequences, 
possibilities of treatment, and its effectivity.  
In summary, this study shows that hepatitis C is still a major comorbidity in the Dutch 
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In comparison with other biotech substitutions, the adoption of recombinant Factor VIII 
(rFVIII) has been relatively slow. We sent a postal questionnaire to all Dutch haemophilia 
patients and haemophilia treating physicians, to determine which factors predict whether a 
patient uses plasma derived FVIII (pdFVIII) or rFVIII and to investigate patients’ and 
doctors’ opinions on both products.  
Fifty-six per cent of patients received rFVIII. This percentage varied widely between centres. 
Only one doctor would choose to use pdFVIII if he would suffer from haemophilia A himself, 
and 74% would choose to use rFVIII. Younger patients, those not infected with HIV or 
hepatitis C, and those who did not have family members who used pdFVIII, switchted more 
often from pdFVIII to rFVIII. Patients who rated themselves as innovative, who had family 
members who used rFVIII, and those who were treated in a large haemophilia treatment 
centre, were also more likely to have switched. For physicians and patients alike, the 
respondents generally did not see large differences between rFVIII and pdFVIII, except for 
the risk of infections and the knowledge on long-term effects (both larger for pdFVIII).  
Although haemophilia patients represent one of the most empowered patient groups, 







In 1995, recombinant Factor VIII (rFVIII) was introduced in the Netherlands for the treatment 
of patients with haemophilia A, as a substitute for plasma derived Factor VIII (pdFVIII ). Of 
the Dutch haemophilia patients who were treated with plasma derived clotting factors before 
1985, 16-17% had become infected with the human immunodeficiency virus (HIV)1,2. In 
addition, the large majority (about 80%) of patients had been infected with hepatitis C3,4. 
Because of this history of infectivity with plasma derived clotting factors, one might have 
expected that rFVIII would have been quickly adopted by the market. This, however, has not 
been the case. In 2001, 6 years after its introduction, rFVIII was used by 50% of the Dutch 
haemophilia patients, while the other 50% continued to use pdFVIII5. Compared with other 
biotechnology substitutions, the uptake of rFVIII is slow. In the Netherlands, both 
recombinant human growth hormone and recombinant human insulin quickly completely 
replaced their organic counterparts, and the recombinant follitropins have captured an 80% 
market share within 4 years6-8. The uptake of rFVIII in the Netherlands has also been slower 
than in other countries. Ireland, Scotland and Denmark have completely switched from 
pdFVIII to rFVIII as a matter of health policy. In France rFVIII represents 80% of all FVIII 
used9, and in Germany it represents 50% .  
Apparently, doctors and/or patients have been hesitant to adopt rFVIII. Explanations may be 
that they fear some unforeseen long-term negative effect caused by the use of rFVIII, or that 
they are concerned about increased antigenicity of rFVIII, as this was debated in the early 
1990s10-12, even though the current scientific believe is that this is not the case13-15. The 
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB) is the 
major provider of pdFVIII in the Netherlands. Loyalty towards this organisation might be 
another reason for the hesitation. As in the past the prevalence of HIV positivity was highest 
in countries that predominantly used FVIII preparations derived from plasma of paid donors 
The uptake of recombinant Factor VIII in the Netherlands 
 
101 
from the USA2, there might be a preference for a Dutch not-for-profit organisation that relies 
on non-paid donors. Also, it has been argued that it is not possible to switch all patients to 
rFVIII, even if they wanted to, because the supply of rFVIII is not sufficient5. Indeed, at the 
time of our study there was a sudden shortage of rFVIII, as Bayer, one of the major producers 
of rFVIII, had suspended market release for its worldwide market16. In addition, there may 
have been doubts about the advertised increased safety of rFVIII with regard to transmission 
of infections. The first rFVIII preparations contained plasma-derived albumin as a stabilizer. 
In 1999 and 2000, three virtually albumin-free formulations (Refacto®, Kogenate Bayer® and 
Helixate NexGen®) were introduced. They contain 1000-times less plasma-derived albumin 
than the former formulations, and have an additional detergent based purification step, aimed 
at further reducing the potential for transmission of infectious agents17.  
As far as we know, the factors that underlie the choice for either plasma derived or rFVIII 
have never been systematically studied. Who is the most influential in choosing between 
pdFVIII and rFVIII: the doctor or the patient? Can the adoption of rFVIII be predicted from 
medical characteristics such as severity of the disease, treatment modality, or infections 
contracted through the use of clotting factors (HIV, hepatitis C)? What do patients actually 
think of the safety and antigenicity of rFVIII and pdFVIII? To address these questions we sent 
a postal questionnaire to all haemophilia patients and all haemophilia treaters in the 
Netherlands. The objective was to investigate the opinions of patients and doctors on the 
choice between pdFVIII and rFVIII, and to determine which factors predict whether a patient 






Mailing procedures  
The study in patients was carried out as part of the Haemophilia in the Netherlands 5 (HiN-5) 
project. During the past 30 years, the effects of changes in haemophilia treatment have been 
monitored by four nation-wide postal surveys among Dutch haemophilia patients conducted 
in 1972, 1978, 1985 and 1992. In April 2001, patients received a letter about the forthcoming 
HiN-5 study on haemophilia. Where possible, this announcement was sent by their physician. 
Other patients were first informed by the Dutch Haemophilia Patients' Society or directly by 
the Study Group HiN-5. All haemophilia patients who were listed with the haemophilia 
treatment centres, with the Dutch Haemophilia Patients' Society, or on updated mailing lists 
from previous survey(s) were included in the mailing. After an extensive search for addresses 
the questionnaire was sent to 1567 patients in May 2001.The closing date for data collection 
for the current study was set at 12 September 2001.  
 
In addition, in May 2001, we sent a postal questionnaire to the 26 directors of the licensed 
haemophilia care centres in the Netherlands. Supplementary questionnaires were included, 
which they were asked to distribute among the colleagues in their department who 
autonomously treated haemophilia patients as well. To enable us to measure the response, we 
requested the directors to report to how many of their colleagues had been given a 
questionnaire. Reminders were sent after two weeks. 
 




The prestructured patient questionnaire in 2001 was largely based on the four previous HiN-
questionnaires. For this study, we added specific questions, which followed from a prior 
model that we developed and that incorporated all factors we assumed to be predictive of the 
choice between recombinant and plasma-derived clotting factors. To formulate this model and 
these questions, literature on clotting factors was consulted, and interviews were held with 
patients and representatives of the Dutch Haemophilia Patients Society, haemophilia-treating 
physicians, and clotting factor producers. Before the questionnaire was actually sent out, a 
small number of patients and a panel of experts was asked to complete the questionnaire and 
to give their comments. These ‘pilots’ were helpful in optimising the structure and content of 
the questionnaire. 
Questions on age, type of haemophilia, severity of disease, treatment modality, inhibitor 
formation, infectious diseases (HIV, hepatitis C), treatment centre, membership of the Dutch 
Haemophilia Patients' Society, education level and net income were included in the HiN-
questionnaires. For this study, items were added: attitude towards innovations 
(innovativeness), aversion against switching, empowerment, first clotting factor used, current 
product used, consideration of future product switch, clotting factor used by family members, 
number of family members with HIV or hepatitis C through the use of clotting factors, most 
important influence in clotting factor choice (respondent himself, physician, or both equally 
influential), physician’s advice (recombinant, plasma derived or neutral), preference for a 
specific producer (Dutch over foreign, not-for-profit over profit making), and opinion on 
albumin-free formulations of rFVIII (5-points scale: large deterioration, deterioration, no 
difference, improvement, large improvement). The first three items are described in Table 1 
and were included at the beginning of the questionnaire, before the issue of recombinant 





Table 1. Selection of items included in the questionnaire for patients and physicians 
Innovativeness 
If a new treatment for haemophilia would become available, e.g. gene therapy, how would you react to 
that? 




5 very positive 
- In general, if a new treatment for haemophilia would become available, when would you adopt it?  
1 never 
2 when the treatment can hardly be escaped anymore 
3 when the treatment is proven superior in a large number of patients, 
4 when the treatment succesful in some other patients 
5 immediately 
- With regard to the adoption of the latest insights and treatments in health care, patients can be 
categorised into five groups. In which group would you place yourself? 
1 laggards (10%) 
2 late majority (35%) 
3 early majority (35%) 
4 early adopters (15%) 
5 innovators (5%) 
 
Empowerment‡ 
- I always make clear to my physician which treatment I prefer myself. 
- I am well informed about the different treatment possibilities for haemophilia. 
- I follow my physician’s advice without questioning.* 
- Besides the information my physician gives me, I look for information about clotting factors 
myself, as well. 
- When my physician proposes a certain treatment, I ask if there are other treatment options as well. 
1 not at all 
2 a little bit 
3 quite a lot 
4 very much 
 
Aversion against switching 
- Switching from one clotting factor product to another may cause problems (e.g. inhibitor 
formation). 
- If you are doing well with your current treatment, you should never change to another clotting 
factor product. 
1 totally disagree 
2 disagree 
3 neither agree nor disagree 
4 agree 
5 totally agree 
‡ the items on empowerment were included in the patient questionnaire only 
* reverse coding 
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From a list of eight characteristics, which may be important to patients in choosing between 
different clotting factor products (price, effectiveness, user friendliness, producer’s image, 
knowledge on long-term effects, risk of infections, risk of product shortages and risk of 
inhibitor formation), respondents were asked to rank the five most important characteristics 
(between 1 and 5 points). The average rating for a product characteristic could be a maximum 
of 5  (if all respondents ranked the characteristic as the most important one), and a minimum 
of 0 (if none of the respondents selected the characteristic in the top-five most important). In 
addition, their opinion on the eight characteristics was asked on a five-points scale (-2 very 
favourable for plasma, -1 favourable for plasma, 0 the same for plasma and recombinant, 1 
favourable for recombinant, 2 very favourable for recombinant). 
 
The questionnaire for doctors mainly contained the same items as the patients questionnaire. 
Items were added on the personal characteristics of the responding doctor, such as age, sex, 
year of graduation from medical school, medical specialism, and whether they treated mainly 
adults, children, or both. In addition, the respondents were asked which type of clotting factor 
they would choose for themselves if they had severe haemophilia (plasma derived, 
recombinant or no preference).  
 
Only the directors, and not their colleagues were asked to fill the characteristics of their 
department’s patient population: number of patients with haemophilia A and B, severity, 
number of patients on plasma-derived and recombinant clotting factors, number of patients 
with inhibitors and number of infections with HIV and hepatitis C. Before the questionnaire 
was actually sent out, two doctors were asked to complete the questionnaire and to give their 






As we were interested in the choice between, and the opinions about rFVIII and pdFVIII, we 
included in the analysis only patients with haemophilia A who had used FVIII during the 18 
months preceding our questionnaire, and for whom we knew whether the first clotting factor 
product used had been recombinant or plasma derived. The type of first clotting factor used 
(recombinant or plasma derived) was investigated in relation to year of birth. In this analysis 
year of birth was used as a proxy for the year of first treatment.  
Subsequently, to study switching behaviour, we included only those respondents who had 
started on plasma derived clotting factor, and excluded the respondents who had started on 
rFVIII, as switching from rFVIII to pdFVIII is very rare. Odds ratios (OR) for the association 
with switching from pdFVIII to rFVIII were calculated by logistic regression for all factors in 
our prior model. The factors that were statistically significantly associated with switching in 
these univariate analyses were subsequently included in a multivariate logistic regression 
model to calculate the adjusted ORs. The severity of haemophilia was classified according to 
the residual percentage of FVIII clotting activity: severe (<1%, i.e. <1 IU/dl), moderate (1-
5%), or mild (>5-40%). Haemophilia treatment centres were categorised into ‘small’ and 
‘large’ centres according to the number of patients (n ≤10, n >10 respectively). Different 
items that were designed to measure one common factor, such as e.g. the three items on 
innovativeness, were clustered together (as the average over the items), if Crohnbach’s alpha 
for correlation was ≥0.70.  
 
To calculate the response in the physicians' questionnaire, we assumed that directors who, 
after the reminder, did not respond to our questionnaire, had not distributed it among 
colleagues either. The departments were categorised into three groups: departments treating 
mainly adults, departments treating mainly children, and those treating both. Personal 
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characteristics of the respondents were described, as were the influences of patient 
characteristics on the doctor’s advice about rFVIII versus pdFVIII. The personal opinions of 
doctors on matters related to the choice between pdFVIII and rFVIII were noted and were 
compared with the opinions of patients. For each respondent (both patients and doctors) the 
opinion on each of the eight product characteristic was multiplied by the importance attached 
to that characteristic. The sum of these eight multiplications was used as a summarising 
measure of the respondent’s opinion on recombinant versus plasma derived clotting factor 
(range -30 to 30). 
 
Results 
Response, participants and first use 
The total response to the patient questionnaire was 69% (n=1,084). Respondents who were 
excluded from the analysis were patients who did not have haemophilia A (n =188), patients 
who had not used FVIII in the past 18 months (n=337, mainly mild haemophilia A), and 
patients for whom the type of first clotting factor used was not known (n=22). In total, 537 
respondents were eligible for analysis. Characteristics of the responding patients are presented 





Table 2. Characteristics of the participating patients 
 First use was rFVIII 
(n=84) 
First use was plasma derived 
clotting factor (n=453)  
Mean age in years (95% CI) 9 (6-11) 37 (35-38) 
Male 84 (100) 444 (99) 
     
Severity of disease     
 mild 25 (31) 85 (19) 
 moderate 16 (20) 81 (18) 
 severe 41 (50) 277 (63) 
     
Treatment modality     
 Home treatment 27 (33) 318 (72) 
 Profylactic treatment 37 (45) 234 (53) 
     
Infectious diseases     
 HIV positive 0 (0) 26 (6) 
 Hepatitis C 4 (5) 284 (67) 
     
(Past) development of inhibitor 5 (7) 51 (13) 
     
Member of Haemophilia Society 72 (86) 344 (77) 
     
High income 39 (62) 215 (52) 
High education 30 (37) 167 (39) 
All values are No. (%) except where otherwise indicated. 
95% CI=95% confidence interval 
 
First treatment had been with rFVIII for 16% (n=84) of the participants, and with plasma 
derived clotting factor for 84% (n=453). Because of the consensus among the Dutch 
haemophilia treaters to treat previously untreated patients (PUPs) with rFVIII, we expected 
that the large majority of respondents who started using clotting factor treatment after 1994 
would start on rFVIII.  
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As we did not have data on the year of first treatment, we used year of birth as a proxy. Of all 
537 respondents, 12% (n=67) was born after 1994. Figure 1 shows that these young patients 

















































Percentage of patients who started on rFVIII versus year of birth 
 
Eighteen directors returned the questionnaire (response 69%). They reported that they had 
forwarded the questionnaire to 18 colleagues. Overall, including colleagues, we received 30 
completed questionnaires (response 30/44=68%). Together, the directors reported 1316 
patients with haemophilia A and 169 patients with haemophilia B in their care. As such, our 
sample represents the treating physicians of >95% of all Dutch haemophilia patients. One 
director was excluded who no longer treated haemophilia patients. A total of 29 participating 
physicians, from 17 departments, remained for analysis. 
Mean age of the physicians was 47 years (ranging 35-61 years). Fifty-nine per cent were men, 




general practitioners, 11% (n=3) internists, 46% (n=13) haematologists, 21% (n=6) 
paediatricians, and 14% (n=4) paediatric haematologists.  
 
Switching behaviour 
For the analysis of switching behaviour, we included the 453 responding patients whose first 
treatment had been with plasma-derived clotting factors. Of these 45% (n=206, switchers) had 
switched from pdFVIII to rFVIII and 55% (n=247, non-switchers) continued to use pdFVIII 
at the time of our questionnaire. 
 
Influence of treating physician 
The 453 responding switchers and non-switchers were treated in 30 different treatment 
centres. Eighty-eight per cent of these patients were treated in seven large centres (median 
number of respondents per centre was 31). In these large centres, the percentage of 
respondents who had switched from pdFVIII derived to rFVIII varied from 26% to 71% 
(median 40%). In the small centres (n=23, median number of respondents per centre was 
one), the percentage of switchers varied from 0% to 100% (median 0%). As such, treatment in 
a large haemophilia treatment centre was positively associated with switching from pdFVIII 
to rFVIII (ORadj. 3.2, 95% CI 1.1-9.8).  
In the responding departments that treated mainly adults (n=8; 501 patients), the proportion of 
patients using rFVIII ranged from 0 to 75% (median 12%), and in the departments that treated 
mainly children (n=6; 167 patients), it varied between 0% and 100% (median 84%). On 
average the proportion of patients using rFVIII was three times higher in departments treating 
children than in departments treating adults (p=0.02).  
To the question 'Who was the most influential in the choice of the type of FVIII product?', 
54% of the patients answered ‘my treating physician’, 25% ‘both myself and my physician’, 
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and 21% ‘ myself’. There was no difference between switchers and non-switchers in this 
respect. Quite similarly, only one doctor indicated the patient to be the most influential in 
choosing a FVIII product. Forty-four per cent of the non-switchers had spoken with their 
physician about the choice between rFVIII and pdFVIII. Only 21% of all patients who did 
discussed the topic with their physician (switchers and non-switchers) initiated the 
conversation themselves. Eight per cent of the non-switchers and 52% of the switchers had 
been advised by their physician to use rFVIII.  
Five of the 29 physicians (17%) gave the same advice to all patients (either pro-pdFVIII, pro-
rFVIII or neutral), while the other 22 doctors gave different advice to different patients. The 
reasons for these differential advices were the limited availability of rFVIII (23%), differences 
between patients (32%), or both (46%). Young patients were preferentially advised to use 
rFVIII by 81% of these physician, and PUPs by 95% (Table 3). Thirty per cent preferred to 
give rFVIII to HIV negative patients. Twenty-nine per cent of the doctors were more inclined 
to advise rFVIII to patients who were afraid of bovine spongiform encephalopathy (BSE) than 
to patients who were not afraid of BSE. Twenty-four per cent took in consideration whether 






Table 3  To which patients do you tend to advise rFVIII instead of pdFVIII? 
 Results are given in percentages (n=22 physicians) 
Patient characteristic Doctor’s preference to advise rFVIII instead of pdFVIII 
Severity of the disease severe haemophiliacs no preference mild haemophiliacs 
 14 76 10 
Previously untreated 
patients (PUPs) 
PUPs no preference previously treated 
patients 
 95 5 0 
Age young patients no preference old patients 
 81 19 0 
HIV HIV positives no preference HIV negatives 
 15 55 30 
Prophylaxis patients on prophylaxis no preference patients not on 
prophylaxis 
 5 91 5 
Home treatment patients on home 
treatment 
no preference patients not on home 
treatment 
 0 100 0 
Family members using 
rFVIII 
patients with family 
members using rFVIII 
no preference patients without family 
members using rFVIII 
 24 76 0 
Compliance compliant patients no preference non-compliant patients 
 5 95 0 
Inquirement patients who do 
inquire about rFVIII 
no preference patients who do not 
inquire about rFVIII 
 10 90 0 
Fear for BSE patients afraid of BSE no preference patients not afraid of 
BSE 
 29 71 0 
HIV=Human Immunodeficiency Virus; BSE=Bovine Spongiform Encephalopathy 




The average age of the switchers (31 years, range 2-78) was lower than of the non-switchers 
(41 years, 5-83). Switching was not associated with severity of disease, history of inhibitor 
formation or home treatment (see Table 4).  
 
Table 4 Univariate and multivariate logistic regression model of switching vs. nonswitching in 
patients 
 ORcrude (95% CI) ORadj.* (95% CI) 
Parameters included in the multivariate model     
Patient characteristics     
Age 0.97 (0.96-0.98) 0.98 (0.96-1.0) 
HIV positivity 0.4 (0.2-1.0) 0.3 (0.1-0.9) 
Hepatitis C infection 0.4 (0.3-0.6) 0.4 (0.2-1.0) 
No. of family members on plasma 0.7 (0.6-0.9) 0.6 (0.5-0.9) 
No. of family members on recombinant 2.0 (1.4-2.6) 2.7 (1.6-4.4) 
Innovativeness (1-5) 1.3 (1.0-1.8) 1.8 (1.1-3.1) 
Profylactic treatment  1.5 (1.0-2.2) 1.4 (0.7-2.8) 
Membership of Haemophilia Patients Society 1.6 (1.0-2.6) 1.4 (0.6-3.4) 
Empowerment (1-4) 1.3 (1.0-1.8) 1.2 (0.7-2.1) 
High income 1.4 (1.0-2.1) 1.4 (0.8-2.7) 
Treatment centre     
Size of treatment centre (small/large) 5.6 (2.6-12.2) 3.2 (1.1-9.8) 
Opinions     
Pro-recombinant opinion (-30 through 30) 1.1 (1.1-1.2) 1.1 (1.1-1.2) 
‘Never change a winning team’ (1-5) 0.7 (0.6-0.9) 0.8 (0.6-1.1) 
Preference for Dutch over foreign producer (1-5) 0.6 (0.5-0.7) 0.8 (0.5-1.1) 
Preference for not-for-profit producer (1-5) 0.7 (0.6-0.8) 0.8 (0.6-1.1) 
     
Other parameters from our prior model     
Severity of disease 1.1 (0.9-1.4)   
(Past) development of inhibitor 1.5 (0.8-2.7)   
Home treatment 1.4 (0.9-2.2)   
No. of HIV positive family members 0.7 (0.3-1.3)   
No. of family members with hepatitis C 1.2 (0.8-1.8)   
High education 1.0 (0.7-1.5)   
Agreement with ‘Switching might cause problems, e.g. 
inhibitors’ (1–5) 
0.9 (0.8-1.2)   
95% CI=95% confidence interval 





Patients who had been infected with HIV or hepatitis C switched less to rFVIII than patients 
who had not been infected (ORadj. 0.3, 95% CI 0.1-1.0). The fact whether patients did or did 
not have family members who had been infected with HIV or hepatitis C through the use of 
clotting factors was not associated with switching behaviour. The more family members were 
using pdFVIII, the less the patients themselves had switched from pdFVIII to rFVIII (ORadj. 
0.7, 95% CI 0.5-0.9). On the other hand, the more family members who used rFVIII, the more 
the patients had switched to rFVIII (ORadj. 2.7, 95% CI 1.6-4.3).  
The three items on innovativeness (Crohnbach’s alpha 0.70), as well as the five items on 
empowerment (Crohnbach’s alpha 0.75) were clustered together in the analysis. In univariate 
analyses both were positively associated with switching from pdFVIII to rFVIII.  
Membership of the Dutch Haemophilia Patients' Society was also higher in the switchers than 
in the non-switchers (81% versus 73%). Net income and education correlated only weakly 
(Crohnbach’s alpha 0.49), and therefore they were not clustered together as one measure of 
socio economic status. In univariate analysis high income was positively associated with 
switching, while high education was not. After adjustment for the other parameters in the 
model (see Table 4), the point estimates for the influence on switching of empowerment, 
income and membership of the Dutch Haemophilia Patients' Society stayed very much the 
same, only the confidence intervals were broader. The influence of innovativeness increased 
after adjustment.  
 
Opinions 
Of the non-switchers, 21% (n=45) was thinking about switching to rFVIII in the future and 
79% (n=167) wanted to continue using pdFVIII. In 2000, two virtually albumin-free 
formulations of rFVIII were introduced. Forty per cent of the switchers, 23% of the non-
switchers and 90% of the physicians knew about the introduction of these albumin-free 
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formulations of rFVIII. Only 35% of the patients gave an opinion on this development, the 
large majority of whom (89%) thought that it was an improvement. Of the 45 non-switchers 
who indicated they were thinking about switching to rFVIII, 21 (47%) had done so since the 
introduction of the albumin-free formulations, and 25 (53%) already before this introduction. 
The large majority of physicians reported that the introduction of albumin-free products had 
not influenced their prescribing behaviour. Eleven percent had started to prescribe rFVIII 
more often. 
 
Fig 2 shows how doctors and patients respectively, rated the importance of the eight 
predefined product characteristics in choosing between rFVIII and pdFVIII. Risk of infections 
was a very important characteristic to both patients and physicians. Doctors attached a lot of 
importance to the knowledge of long-term effects, while patients, and especially the non-
switchers were very much concerned with the effectiveness.  
Fig 2. Importance of product characteristics in choosing 











































































If the physicians hypothetically suffered from severe haemophilia A themselves, 74% would 
choose to use rFVIII, 4% pdFVIII, and 22% had no preference. 
The majority of both doctors and patients thought that the risk of infection was larger with 
pdFVIII than with rFVIII (Fig 3a).  
































The uptake of recombinant Factor VIII in the Netherlands 
 
117 
On the other hand, they were also of the opinion that for rFVIII,  less is known about the 
long-term effects (Fig 3b). 
 
Switchers answered these questions more favourable for rFVIII than non-switchers did. All 
doctors and the large majority of the patients (73%) considered rFVIII and pdFVIII equally 
effective. The remaining minority of patients was divided: switchers believed rFVIII to be 
more effective, while non-switchers believed the opposite. Also on the topic of inhibitor 
formation, the majority of the patients (57%) and doctors (82%) did not percieve a difference 
between rFVIII and pdFVIII (Fig 3c). With respect to the risk of product shortages, the 
respondents were divided (Fig 3d).  
 
To the question 'Have you been troubled by shortages of FVIII product during this year or last 
year (2000+2001)?', 27% (n=56) of switchers and 7% (n=16) of non-switchers answered in 
the affirmative. The large majority of the participants (67% and 75% of patients and doctors 
respectively) rated the image of the producers of rFVIII and of pdFVIII as equally good. To 
the remaining switchers the image of rFVIII producers was better, while the opposite was true 
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Non-switchers expressed the strongest preference for a Dutch, not--profit-making producer 
(Fig 3e and 3f).  On average, switchers were more positive about rFVIII (summarised score 6 
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The correlation between the two items measuring aversion against switching of clotting factor 
in general was too low (Crohnbach’s alpha 0.42) to cluster them together in the regression 
analysis for patients (Table 4). 
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With the statement “Switching from one clotting factor product to another may cause 
problems”, most patients neither agreed nor disagreed while most doctors (48%) disagreed 
(Fig 3g). Thirty-nine per cent of the switchers and 51% of the non-switchers agreed with the 
notion to “never change a winning team” (Fig 3h).  
 
Discussion 
From 1995 onwards, nearly all children who received FVIII for the first time (PUPs), were 
prescribed rFVIII. From all responding patients who had started using pdFVIII in the past, 
45% had switched to rFVIII and 55% continued to use pdFVIII until the time of our 
questionnaire.  
The percentage of patients who had switched from pdFVIII to rFVIII varied from 0% to 100% 
in small centres and from 26% to 71% in large centres. The proportion of patients using 
rFVIII was on average 2.9 times higher in departments treating mainly children than in 
children treating mainly adults. Even within the groups of child departments and adult 
departments, the proportion of patients using rFVIII varied tremendously. From this large 
variability, one may conclude that the treating physician strongly influences product choice. 
This conclusion is further strengthened by 41% of the doctors and 54% of the patients, 
regarding the treating physician as the most influential person in choosing a clotting product. 
Unfortunately, the number of departments was too small to investigate whether the opinions 
or the innovativeness of the physicians within a department were predictive of the proportion 
of patients on rFVIII. 
 
Notwithstanding the physicians’ strong influence, our results do show a small influence of the 
patients as well in the choice between pdFVIII and rFVIII. The majority of physicians 




choice of family members. Therefore, the association of these factors must go largely through 
patient preferences and not through physicians’ policies.  The same holds true for 
innovativeness of patients and opinion on rFVIII. Also, there seems to be a weak association 
in patients between preferring a Dutch, or a not- profit-making producer, and continued use of 
pdFVIII. The interpretation of these results is, of course, complicated by the cross sectional 
characteristic of our data. We cannot determine, for example, whether a favourable opinion on 
rFVIII caused people to switch, or whether the switch caused the favourable opinion. 
As there are no clear guidelines on which patients to switch from pdFVIII to rFVIII, we 
hypothesised that physicians mainly switched those patients who especially asked to be 
treated with rVIII, which we expected to be the most empowered patients, members of the 
Dutch Haemophilia Patients' Society or patients with a higher social economic status. Except 
for the absence of an effect of high education, our hypothesis was confirmed by the data. 
After the many years of discussion about the perceived increased antigenicity of rFVIII, it is 
remarkable that only 13% of the patients thought rFVIII to be more antigenic than pdFVIII.  
 
In the preparatory interviews, which we conducted to construct the questionnaire for patients, 
we learned that the haemophilia treating physicians, jointly with the Dutch Haemophilia 
Treatment Society, had agreed at the launch of rFVIII to introduce this new product very 
gradually to build up experience and to minimise the risk of shortages. They reasoned that a 
sudden and complete switch to rFVIII, would mean the end of the production of pdFVIII by 
the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), the 
major provider of plasma derived FVIII (pdFVIII) in the Netherlands. They preferred to keep 
both the CLB and the producers of rFVIII in business, as history had showed that dependence 
on a single producer makes one vulnerable. The physicians have indeed adhered to this 
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agreement. Still, if they had suffered from haemophilia A themselves, only one doctor would 
choose to use pdFVIII, and 74% would choose to use rFVIII.  
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A wide range of factor VIII and IX levels is observed in heterozygous carriers of hemophilia, 
as well as in non-carriers. In female carriers extreme lyonisation may lead to low clotting 
factor levels. We studied the effect of heterozygous hemophilia carriership on the occurrence 
of bleeding symptoms.  
A postal survey was performed among the majority of all women who were tested for 
carriership of hemophilia in the Netherlands between 1985 and 2001. The questionnaire 
included items on personal characteristics, characteristics of hemophilia in the affected family 
members, carrier testing and history of bleeding problems such as bleeding after tooth 
extraction, bleeding after tonsillectomy and operations. Information on clotting factor levels 
was obtained from the hospital charts. Logistic regression was used to assess the relation of 
carrier status and clotting factor levels with the occurrence of hemorrhagic events.  
In 2004, 766 questionnaires were sent, 546 women responded (80%). Of these 274 were 
carriers of hemophilia A or B. The median clotting factor level of carriers was 0.60 IU/ml 
(range 0.05-2.20 IU/ml) compared to 1.02 IU/ml (range 0.45-3.28 IU/ ml) in non-carriers. 
Clotting factor levels between 0.60 and 0.05 IU/ml were increasingly associated with 
prolonged bleeding from small wounds, prolonged bleeding after tooth extraction, 
tonsillectomy and operations.  
Carriers of hemophilia bleed more than other women, especially after medical interventions. 
Our findings suggest that not only clotting factor levels at the extreme of the distribution, 
resembling mild hemophilia but also mildly reduced clotting factor levels between 0.41 and 





Hemophilia is an X-linked hereditary bleeding disorder caused by a deficient or defective 
coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Resulting from the 
recessive X-chromosomal inheritance pattern mostly men are affected and their female 
relatives can be heterozygous for the mutation, often referred to as carriers of hemophilia.  
Previously, pedigree analysis and clotting factor VIII or IX levels were used to diagnose 
carriership hemophilia1. In the early nineteen eighties it became possible to ascertain the 
carrier status by means of DNA analysis, which has evolved from haplotyping, to mutation 
analysis offering certainty about the carrierstatus2. During the last three decades genetic 
counseling, carrier testing and prenatal diagnosis of hemophilia have become an integrated 
part of the comprehensive care for hemophilia3.  
Female carriers are expected to have a plasma concentration of FVIII or IX corresponding to 
half the concentration found in healthy individuals, which is generally sufficient for normal 
hemostasis. However, in carriers a wide range in clotting factor levels is seen, from very low, 
resembling affected males, to the upper limit of normal 4.  This range has been attributed to 
X-chromosome inactivation, which takes place in the early embryonic life5. Other genetic 
factors, such as ABO blood group, may also affect factor VIII and FIX plasma concentrations 
in carriers, as they do in non-carriers, where a wide distribution is observed, too6.  
Although Merskey et al7 already reported excessive bleeding after tooth extraction in 47% of 
known carriers (n=19) in 1952, this first publication was not followed by  larger studies.  
Some case series showed joint bleeds, prolonged bleeding after tonsillectomy or tooth 
extractions or post-partum bleeding8-13. It is important to assess the risk of bleeding in carriers 
of hemophilia, to assist help physicians in improving care for hemophilia carriers, for instance 
by the implementation of prophylactic intervention in carriers at risk for bleeding.  
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While extensive information on bleeding in men with hemophilia is available, only a few 
studies have focused on bleeding in carriers. We present a large national cross-sectional study 
examining bleeding in women in whom genetic testing for hemophilia was performed within 
the last decade. We focused on spontaneous bleeding and bleeding following surgical 
interventions.  
Objectives:  
The aim of this study was to examine the risk of bleeding among carriers of hemophilia A or 




We contacted all women who had been tested for carriership of hemophilia A or B before 
2001 in the Netherlands. All women had to be 18 years or over to participate. Diagnosis of 
carriership of hemophilia consisted of DNA diagnostics, pedigree analysis or the assessment 
of clotting factor levels. Carriers of hemophilia were women in whom the genetical defect 
related to hemophilia was established through DNA analysis (haplotype or mutation analysis) 
or, before 1985, through the determination of clotting factor levels in combination with 
pedigree analysis. Non- carriers were women in whom testing showed that they were not 
carrying the mutation that caused hemophilia A or B in their family. By comparing carriers 
and non-carriers both from hemophilic families we excluded the possible bias introduced by 






Questionnaires were sent by postal mail, followed by two reminding letters. The questionnaire 
included items on personal characteristics, type and severity of hemophilia in affected 
relatives, carrier testing and several bleeding problems. We assessed if patients ever reported 
spontaneous bleeding and bleeding after trauma: bruising, nose bleeds, gum bleedings and 
joint bleeds. Questions on bleeding after medical interventions included bleeding after tooth 
extractions, (adeno) tonsillectomy and operations.  Prolonged bleeding after medical 
interventions was defined as bleeding for over three hours after tooth extractions, (adeno) 
tonsillectomy or operations. The topics on bleeding were based on a validated questionnaire 
developed by Šrámek et al, validated by means of sensitivity analysis14.  Restrictions in daily 
life due to excessive blood loss during the menstrual period were measured on a seven-point 
scale in which the score one represented no restrictions and seven points severe restrictions. 
To evaluate the questionnaire a pilot study was performed in 12 carriers. Informed consent 
was obtained to allow us to verify the diagnosis and to obtain information on factor VIII and 
IX activity from the hemophilia treatment centres. In most women clotting factor activity had 
been determined at several time points, in which case the lowest value was used for 
evaluation in this study.  Severity of hemophilia in the male family members was classified 
according to residual percentage of factor VIII or IX clotting activity: severe (<0.01 IU/ml), 
moderate (0.01-0.05 IU/ml) or mild (>0.05-0.40 IU/ml).  The Committee of Medical Ethics of 
the Leiden University Medical Center approved this study.  
 
Data analysis 
Women with clotting disorders due to other causes than hemophilia or who used 
antithrombotic medication were excluded from the analysis. The prevalence of bleeding 
symptoms in women who were carriers of hemophilia A or B was compared to that of women 
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not carrying a hemophilia mutation. Due to the limited number of women reporting 
hemophilia B in the family we could not distinguish between the two types of hemophilia in 
the analysis. The risk of bleeding related to the carrier status and clotting factor levels was 
determined, and we tested for a graded response using a Wald test. If in the comparison 
between carriers and non-carriers a specific bleeding event showed a relative risk (RR) above 
1 and a 95% confidence interval (CI) not including one, its association with clotting factor 
levels is also presented.  In the analysis of bleeding risk caused by specific interventions only 
women who ever underwent this intervention were included in the analysis. Women who 
were treated with cyclokapron (tranexamic acid), desmopressin or clotting factor preparations 
before the medical intervention were excluded from the analysis. Clotting factor levels were 
analyzed as a categorical variable, the studied categories were <=0.40 IU/ml, 0.40-0.60 IU/ml 
and >0.60 IU/ml. In the analysis of excessive blood loss during the menstrual period only 
women were included who were pre-menopausal. To exclude the effect of referral for carrier 
testing because of bleeding problems we repeated the determination of the risk of bleeding 
after (adeno) tonsillectomy or operations among women who were not tested because of an 
increased bleeding tendency.  
 
Results  
Response and patient characteristics 
A total of 766 questionnaires were sent, and 546 questionnaires were completed and returned 
(response of 80%). Excluded from analyses were women who reported other clotting 
disorders than hemophilia (19 women of whom 13 had Von Willebrands disease) and 10 
women in whom the carrier status was not conclusive or unknown. This resulted in 274 
carriers and 245 non-carriers for the current analyses. Of these, 73% (n=384) reported 




of hemophilia in the family was unknown. Table 1 shows the general characteristics 
according to hemophilia carrier status. The median age of the carriers and non-carriers was 
similar, 39 years (yrs) (range 18-77 yrs) and 40 years (range 20-90 yrs), respectively.  
 
Table 1. General characteristics of study population 
 Carrier of hemophilia 
 Yes (n=274) No (n=245) 
   
Mean age at questionnaire (range) 39 (18-77) 40 (20-90) 
   
Use of oral contraceptives* 79 (29) 65 (27) 
   
Family   
Severe hemophilia in family 140 (51) 113 (46) 
Hemophilia A in family 230 (84) 151 (62) 
   
Clotting factor   
Clotting factor levels available  225 (82) 143 (58) 
Median FVIII activity (IU/ml)  0.60 (0.05-2.19) 1.02 (0.45-3.28) 
   
Data presented are numbers (percentages) of median (range) 
*Current use of oral contraceptives 
** hemophilia in family, not including own children 
 
Current use of oral contraceptives in carriers and non-carriers was similar, 29 % and 27% 
respectively. Past use of oral contraceptives was reported by 159 carriers (51%) and by 119 
non-carriers (56%). Severe hemophilia in the family was reported by 140 (51%) of carriers 
and 113 (46%) non-carriers. Thirty-one carriers (11%) and 42 non-carriers (21%) were not 
aware of the severity of hemophilia within their family. Carrier testing by means of DNA 
diagnostics, available in the Netherlands since 1985, was performed in 177 carriers (57%) and 
in 122 non-carriers (58%). 
 
Bleeding in carriers of hemophilia 
 
133 
Factor VIII and IX characteristics  
Clotting factor levels were missing for 18 % (49/274) of carriers and 43% (103/245) of non-
carriers. The median clotting factor level in carriers was 0.60 (range 0.05-2.19) IU/ml 
compared to 1.02 (range 0.45-3.28 IU/ml) in non-carriers. Sixty-two women had a clotting 
factor levels lower than 0.40 IU/ml,  all  carriers. Figure 1 shows the distribution of clotting 


































Figure 1. Clotting factor level in relation to carrier status shown for participants of whom clotting factor level is 
known.  
This box-whisker plot shows the median and the interquartile range of clotting factor activity levels in carriers and non-





Bleeding symptoms  
Spontaneous bleeding and bleeding after trauma  
Table 2a presents the risk of (ever having experienced) bleeding of carriers compared to non-
carriers. The risk of prolonged bleeding (>5 minutes) from small wounds was two times 
higher (relative risk (RR) 2.2, 95% confidence interval (CI) 1.4-3.5) in carriers compared to 
non-carriers.  
 
Table 2a. Spontaneous bleeding or bleeding after trauma in carriers and non-carriers of hemophilia 




Relative Risk (CI)* 
    
Nose bleeds    
 Ever reported 115/270 (43) 105/237 (44) 1.0 (0.8-1.2) 
    
Bruising 50/269 (19) 42/243 (17) 1.1 (0.7-1.6) 
    
Small wounds 56/262 (21) 23/237 (9) 2.2 (1.4-3.5) 
    
Gum bleeding    
 Present (yes/no) 164/271 (60) 148/243 (61) 1.0 (0.9-1.1) 
    
Joint bleeds 23/271 (8) 11/240 (5) 1.9 (0.9-3.7) 
 
Data presented are numbers(percentage)  
*CI= 95% Confidence Interval 
 
 
Table 2b. Risk of bleeding after medical interventions 
 
 Carriers Non-carriers RR (CI)* 
    
Tooth extraction†    
 Prolonged bleeding (> 3 hours) 61/228 (27) 26/219 (12) 2.3 (1.5-3.4) 
 Treatment after intervention 24/228 (11) 1/219 (0.5) 23.1 (3.1-169) 
    
Tonsillectomy or adenotomy†    
 Prolonged bleeding (>3 hours) 29/123 (24) 16/122 (13) 1.8 (1.0-3.1) 
 Treatment after intervention 10/123 (8) 1/122 (0.8) 9.9 (1.3-76.3) 
    
Operations†    
 Prolonged bleeding (> 3 hours) 52/170 (31) 19/146 (13) 2.9 (1.6-5.3) 
 Treatment (ever) 16/174 (9) 6/149 (4) 2.3 (0.9-5.7) 
 Blood transfusion 29/174 (17) 18/149 (12) 1.4 (0.8-2.4) 
    
Data presented are frequencies (percentage) 
*RR (CI)= Relative Risk (95% Confidence Interval) 
†Participants who had been treated prior to the clinical intervention with clotting factor preparations, cyclokapron or 
desmopressin were excluded from the analysis.  
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Low clotting factor levels were associated with an increased occurrence of prolonged 
bleeding from small wounds and joint bleeding (Table 3). Joint bleeds were reported by 8% of 
carriers and by 5% of women not carrying hemophilia, which was a two times increased risk 
(RR1.9 CI 0.9-3.7). Although no higher risk of nose bleeds was observed in carriers compared 
to non-carriers, prolonged nose bleeding occurred more often in carriers:  9% of carriers had 
nose bleeds that lasted longer than 10 minutes compared to in 2% of non-carriers. Seventeen 
percent of carriers had received treatment for nosebleeds, compared to 10% of non-carriers. 
Carriers of hemophilia did not have a higher risk for large bruising and gum bleeding.  
 
 
Table 3. Bleeding tendency according to decreasing clotting factor level 
 
 > 0.60 IU/ml 0.40-0.60 IU/ml <0.40 IU/ml p for trend 
Small wounds     
Frequency (%) 28/233 (12) 25/64 (39) 11/60 (18)  
RR (CI)* 1 3.3 (2.0-5.2) 1.5 (0.8-2.9) 0.009 
     
Joint bleeds      
Frequency  12/241 (5) 9/65 (14) 6/62 (10)  
RR (CI) 1 2.8 (1.2-6.3) 1.9 (0.8-4.9) 0.06 
     
Tonsillectomy     
Frequency (%) 21/124 (17) 6/26 (23) 11/31 (35)  
RR (CI) 1 1.4 (0.6-3.0) 2.1 (1.1-3.9) 0.06 
     
Tooth extraction     
Frequency (%) 18/139 (13) 14/51 (27) 15/36 (42) 0.00 
RR (CI) 1 1.8 (1.0-3.0) 2.5 (1.5-4.2)  
     
Operations     
Frequency (%) 18/139 (13) 14/49 (29) 15/36 (42) 0.00 
RR  (CI) 1 2.2 (1.2-4.1) 3.2 (1.8-5.7)  
     
Bleedingscore>=2 1 3.0 (1.5-5.8) 4.0 (2.1-7.7) 0.00 
     
Women who ever received treatment with clotting factor concentration, cyclokapron or desmopressin before tooth extraction, 
tonsillectomy of operations were excluded from the analysis.  





Bleeding after medical interventions 
Tooth extractions had been performed in 228 carriers and 219 non-carriers, and the risk of 
bleeding for more than three hours after tooth extraction was two times higher in carriers 
compared to non-carriers (RR 2.3 CI 1.5-3.4) (Table 2b). In 24 of 228 carriers additional 
treatment due to bleeding after tooth extractions had been required, compared to one of 219 
non-carriers. Treatment included intervention by a dentist or the use of cyclokapron, 
desmopressin, or administration of clotting factor concentrate. Clotting factor levels below 
0.60 IU/ml were associated with prolonged bleeding after tooth extraction.  A total of 123 
carriers and 122 non-carriers underwent tonsillectomy and or adenotomy, 24% of carriers and 
13% of non-carriers reported bleeding for more than three hours following tonsillectomy 
(RR=1.8, CI 1.0-3.1). Six carriers and one non-carrier (1%) were treated prophylactically with 
either cyclokapron or desmopressin before the intervention. In eight carriers (3%) a blood 
transfusion was required after (adeno) tonsillectomy compared to none of the non-carriers. 
Eleven per cent of women carrying hemophilia needed treatment for bleeding following 
surgery. In the majority of cases a second intervention to treat bleeding had to be performed. 
Decreasing clotting factor level were also associated with prolonged bleeding after (adeno) 
tonsillectomy. Women with a clotting factor level of 0.4 IU/ml or below had a 2.1 times 
(RR=2.1, CI 1.1-3.9) increased risk compared to women with a clotting factor level above 0.6 
IU/ml. Prolonged bleeding for more than three hours after one or more operations was 
reported by 52 of 170 carriers and by 19 of 146 non carriers, RR=2.9 (CI 1.6-5.3). Women 
with a clotting factor level of 0.4 IU/ml or below had a three times (RR=3.2, CI 1.8-5.7) 
increased risk of prolonged bleeding after operations compared to women with a clotting 
factor level of 0.6 IU/ml and above.  
Additional treatment during or after surgery due to bleeding problems was necessary in 
12%(51/421) of the carriers and in 5% (13/270) non-carriers. One or more blood transfusions 
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were required in 11% of operations in participants carrying hemophilia compared to 7% in 
non-carriers. Other additional treatment consisted of infusion of clotting factor concentrate or 
a second operation.  
After the exclusion of women in whom bleeding problems were not the indication for carrier 
testing the risks of prolonged bleeding after operations (RR=2.8 CI 1.6-5.0) or tonsillectomy 
(RR=1.8 CI 0.9-3.4) was similar to the finding in the whole study population. 
 
Excessive bleeding during the menstrual period 
Women with lower clotting factor levels reported more often excessive blood loss during the 
menstrual period (menorrhagia) (Table 4).  
 
Table 4. Characteristics of the menstrual period in relation to clotting factor level 
 >0.60 IU/ml 0.4-0.60 IU/ml 0-0.40 IU/ml p for trend 
Excessive blood loss     
Frequency 93/195 (48) 31/54 (57) 31/51 (61)  
Risk 1 1.2 (0.9-1.6) 1.3 (1.0-1.7) 0.07 
     
Anemia     
Frequency 16/195 (8) 9/54 (17) 8/51 (16)  
Risk 1 2.0 (1.0-4.3) 1.9 (0.9-4.2) 0.07 
     
Iron suppletion     
Frequency 15/195 (8) 11/54 (20) 7/51 (14)  
Risk 1 2.6 (1.3-5.4) 1.8 (0.8-4.1) 0.07 
     
Hysterectomy*     
Frequency 7/44 (16) 2/10 (20)  2/11 (18)  
Risk 1 1.3 (0.3-5.2) 1.1 (0.3-4.8) 0.9 
     
Restrictions in daily life† 17/189 (9.0) 9/53 (17) 9/49 (18)  
 1 2.0 (0.8-4.9) 2.3 (1.0-5.6) 0.04 
*Reported by postmenopausal women due to excessive blood loss.  




Similarly, the risk for requiring iron suppletion was 80% increased (RR 1.8 CI 0.7-5.0) in 
women with a clotting factor level of 0.40 IU/ml or below compared to women with a clotting 
factor level of 0.6 IU/ml and above.  Sixty-two (23%) women carrying hemophilia visited the 
general practitioner for excessive bleeding during the menstrual period, compared to 20% 
(n=47) of non-carriers. Fifty-eight women (31 carriers (11%) and 21 non-carriers (9%)) 
consulted a gynecologist and in 18 women a hysterectomy was performed for this reason. 
Mild to severe restrictions in daily life due to excessive blood loss during the menstrual 
period was reported by 18% of women with a low clotting factor level compared to 9% of the 
women with a clotting factor level above 0.60 IU/ml  (RR=2.3 CI 1.0-5.6).  
 
Discussion 
Although hemophilia is a well-known bleeding disorder in men, it is seldom recognized that 
female carriers of hemophilia might not only have an increased bleeding tendency, but that 
the symptoms may be frequent and severe. We studied the risk of bleeding among carriers of 
hemophilia A or B compared to that of non-carriers. Although usually a level of 0.40 IU/ml is 
used as the upper limit defining hemophilia, we found an increased risk of bleeding in women 
with clotting factor levels between 0.40 and 0.60IU/ml. Carriers of hemophilia experience 
more spontaneous and provoked hemorrhages than non-carriers, with a higher risk of 
prolonged bleeding after operations, tooth extractions, tonsillectomy. The risk is highest in 
those with the lowest clotting factor levels.  
 
Strengths and limitations 
In this study we approached all women who had been counseled and tested for carriership of 
hemophilia A or B in the Netherlands. Eighty per cent of women responded to the 
questionnaire. We included 519 women, which makes this currently the largest survey into 
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the hemorrhagic risk in female relatives of men with hemophilia. Non-responders were 
somewhat older than the responders.  Yet, age did not modify the association between the 
clotting factor levels and the risk of bleeding. We therefore assume our results to be 
generalizable to carriers of hemophilia in general. Recall bias may have influenced the 
reporting of bleeding symptoms as questions were asked after carrier testing.  Yet, Mauser-
Bunschoten et al showed by comparing bleeding tendency in obligatory carriers with normal 
factor VIII levels to non-carriers that the awareness of carrier status has little influence on the 
reported frequency of bleeding10. A more serious problem is that women, who grew up in 
families with hemophilia patients, may judge bleeding symptoms differently from women in 
the general population. Selection bias may have been introduced if carrier testing was done 
because of bleeding problems. To counter this problem, as well as the possible 
incomparability of carriers from hemophilia families to women from the general population, 
we only included women from families known with hemophilia. The carriers and non-carriers 
in our study had grown up in the same environment and had not been aware of their carrier 
status until testing. Therefore, even if carrier testing was done because of bleeding symptoms, 
which was the case in 7% of participants, this would not have affected the comparison. 
Clotting factor levels were missing for 18% of carriers and 43% of non-carriers. Although the 
group of women in whom clotting factor levels had been measured is most likely to be 
different from the group in whom these are missing this will not affect the observed relation 
between clotting factor levels and bleeding.  
 
In the literature mild hemophilia is defined as a clotting factor level of below 0.40 IU/ml. This 
cut-off point is also described in the guidelines set by the subcommittee of the ISTH15 and is 
used in clinical practice.  Our study shows that the risk of bleeding is increased in women 




between 0.40 and 0.60 IU/ml. These findings could have implications for the currently used 
definition of clotting factor levels considered to be "reliable" to perform medical 
interventions.  
 
We found a moderately increased risk of joint bleedings in carriers. As joint bleedings are 
relatively rare the reported joint bleeds may be overestimated and they may have been 
confused with superficial bleeding of tissue in the joint region.  
 
Our study mainly shows an increased risk of bleeding after trauma and medical interventions, 
which is similar to the clinical profile of mild hemophilia, and in line with a previous study in 
carriers10. Our findings underline the importance for clinicians and carriers to be aware of the 
complications that may occur after operations in carriers of hemophilia. Both the clinician and 
the carrier should be informed on the clotting factor level, which is strongly related to the 
hemorrhagic risk.  
 
However in many carriers the clotting factor levels were either not measured or not known to 
the woman. It is clear that not only in obligatory carriers, like daughters of hemophilia 
patients, but also in potential carriers clotting factor levels should be measured preceding a 
medical intervention, also at a young age. The clotting factor levels in carriers are 
independent of severity of hemophilia within the family and vary from person to person16 . 
This indicates the importance of clotting factor measurement during carrier testing in all 
women related to men with hemophilia, independent of the severity of hemophilia and family 
history.  
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In conclusion our study suggests a higher risk of bleeding in carriers of hemophilia related to 
clotting factor levels especially after medical interventions. This implicates the importance of 
the measurement of clotting factor levels before interventions in all carriers and potential 
carriers of hemophilia.   
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Hemophilia is a hereditary bleeding disorder affecting both mortality and morbidity. Since the 
discovery by Judith Poole of cryoprecipitate and the introduction of clotting factor preparations 
in the 1970s the prospects for patients with hemophilia have improved considerably1. This was 
offset by disease due to blood borne viruses, such as the human immunodeficiency virus (HIV) 
and hepatitis C virus (HCV). Since 1985 clotting factor preparations have been safe for HIV 
and since 1992 also for transmission of hepatitis C.  
 
The aim of this thesis was to describe temporal changes in the medical and social situation of 
patients with hemophilia. In addition we examined the hemorrhagic tendency of female 
relatives of hemophilia patients. In the present chapter we discuss our considerations regarding 
the methods we used and the validity of our findings. In addition we discuss potential 




We performed two cross-sectional surveys. The first survey was the fifth of a national cross-
sectional study that periodically collected information on the medical and social situation of 
patients with hemophilia in the Netherlands, the Hemophilia in the Netherlands (HiN) study. 
Patients' ascertainment was through the membership of the Netherlands Hemophilia Society, 
the hemophilia centers and by updated mailing lists from previous surveys.  
Comparison over time was made possible by the repeated use of similar pre- structured 
questionnaires that included items on treatment, the annual number of bleeding episodes, the 
use of inpatient hospital care and hepatitis C and HIV infections. The number of participating 




of specialized hemophilia treatment centers and an increasing interest for treatment of all 
patients with hemophilia, including patients with mild hemophilia, contributed to this growth. 
The cooperation in this project between the Netherlands Hemophilia Society, hemophilia 
treatment centers and the Netherlands Society of hemophilia treating physicians added to the 
national character of the HiN study. It is likely that we have been able to address all Dutch 
patients with hemophilia. The extensive time period of 30-years covered by the project and its 
national character make the Hemophilia in the Netherlands an unique project. Because of the 
HiN surveys hemophilia has become one of the best-described rare diseases in the Netherlands. 
The second survey was performed among all women who underwent carrier testing of 




The biggest threat to the validity of studies of a descriptive nature is non-participation. Subjects 
who participate differ, by definition, from those who do not respond, although not necessarily 
on aspects relevant to the research question of the study. In virtually every survey, only a 
proportion of those who are eligible to participate do so. The result of the difference between 
these groups affects the generalizability of the study results. In the HiN-5 study response was 
70%. Non-responders to the questionnaire may have been less severely affected, failing to see 
the need for a survey in this population. However in the non-responders the distribution of 
severity was similar to the participants. As age and type of hemophilia were also comparable 
therefore we consider the results of the HiN-5 study to be generalizable to all Dutch hemophilia 
patients.  Mortality of patients with hemophilia was studied among those who had participated 
in the Hemophilia in the Netherlands-4 survey in 1992. In the HiN-4, it was estimated that 93% 




participate. As again no differences in the distribution of severity and age were observed 
between the responding and the non-responding individuals we considered our data to be 
generalizable to the Dutch hemophilia population.  
Response in the cross-sectional study among women who had been tested for carriership of 
hemophilia A or B between before 1985 and 2001 in the Leiden University Medical Center and 
the University Medical Center Utrecht was 80%. In this period, these were the two centres 
where carrier testing was offered, and therefore they performed virtually all carrier tests for 
hemophilia in the country. We included 519 women, which made our study currently the largest 
survey into the hemorrhagic risk in female relatives of men with hemophilia. In the non-
response group the average age was slightly higher than in the response group. Since clotting 
factor levels increase with age we may have somewhat overestimated the bleeding frequency in 
our study population. This however has no effect on the comparison between bleeding 
frequency in carriers and non-carriers.  Selection bias might have been introduced when carrier 
testing was done because of bleeding problems. As this was reported by a limited number of 
women we do not think this will affect the comparison between women included in our study 
and women from the general population eligible for carrier testing for hemophilia.  To counter 
the problem of the possible incomparability of carriers from hemophilia families to women with 
the general population, we only included women from families with hemophilia. The carriers 
and non-carriers in our study had grown up in the same environment and had not been aware of 
their carrier status until testing. As these women are confronted with hemophilia and the related 
bleeding problems during life they may report bleeding more often or may find this less 






As in every study using questionnaires the value of self-reported data may not be as precise as 
information from the laboratory or a medical chart. Although this may be a disadvantage, self-
reported data offer the opportunity to get an insight into the patient's own perception of his 
situation. Moreover, many relevant data are not reported in medical charts, or not even known 
to the physician. To avoid errors in the severity and type of hemophilia these data were verified 
with the treating physicians. In the study regarding hepatitis C (chapter 2.4) a validation study 
was performed for a group of patients from two large treatment centers showing a high 
correspondence between self-reported hepatitis C status and the hepatitis C status reported by 
the treating physician. As patients with hemophilia, especially those with severe forms, are 
confronted with their disease every day, they are well informed of their treatment and medical 
situation. They are undoubtedly better able to respond to questions on social participation, 
education, and absence from work and school, bleeding frequency and quality of life than their 
physicians. We therefore consider our data to be a reliable overview of the situation of 
hemophilia patients in the Netherlands.    
In the study on mortality the vital status of patients was determined either by the response to the 
questionnaire in 2001, or from the treating physicians, or from the municipal registries. It is 
unlikely that any distortion could have occurred with regard to overall mortality data. 
Theoretically, because the treating hematologist or the general practitioner reported the causes 
of death there may have been discrepancies on causes of death with the general population data 
gathered through the Central Bureau of Statistics. We do not expect this to be of large 
influence. In the study examining bleeding in female relatives of hemophilia patients in a cross 
sectional design the bleeding symptoms were ascertained in women who were aware of their 
carrierstatus. This may have implications for the interpretation of the results. One could argue 




status, and that ideally women should have been questioned prior to carrier testing. Carriers 
may have overreported bleeding symptoms because they are more aware of their status. Yet, a 
previous study suggested little influence of awareness of carriership of hemophilia on responses 
to questions on bleeding 2. Yet, our findings may in part reflect the association between 
awareness of carrier status and an expected tendency to bleed. However, many women and 
physicians are unaware of the relationship between bleeding and carriers status of hemophilia. 
 
Implications for care of patients with hemophilia 
Our data give insight in the current situation of patients with hemophilia, which is important for 
both clinicians and patients. We showed that many improvements have been achieved, a 
reduction in the annual number of hemorrhages, in the percentage of admitted patients and in 
absence from both school and work. Besides these improvements we emphasize that the 
prevalence of perceived joint impairment among young patients did not show the decrease we 
expected. This group of patients merits extra attention during follow-up of patients in a clinical 
setting.  
In chapter 2.1 we emphasize the persisting influence of viral infections on mortality of 
hemophilia patients. Treatment of the effects of viral infections, particularly HIV and hepatitis 
C virus, will result in an improved survival of patients with hemophilia.  
In the Netherlands guidelines for the treatment of hemophilia were drawn up during a 
consensus meeting in 1996. According to these guidelines in patients with severe hemophilia 
prophylactic treatment is preferable to on demand treatment3. An international consensus 
meeting also stated that despite the lack of controlled studies, long-term prophylaxis should be 
the standard for treating children with severe hemophilia in developed countries. No data are 
available for forming a consensus on stopping prophylaxis in adult patients. Our findings show 




raises the question whether the guidelines should be reconsidered or adjustments should be 
made in treatment strategies prescribed by treating physicians. Various aspects should be taken 
into consideration in answering this question, for instance, the burden of treatment for the 
patient and his relatives associated with frequent venapunctures and financial constraints. Our 
data may be a starting point for revision of the guidelines.  
Treatment of patients with hemophilia should become more individualized. From a previous 
study it has become clear that some patients, especially adolescents, tend to interrupt their 
prophylactic treatment schedule for a short or longer period5. Overall these were patients with a 
milder phenotype. In determining the right treatment schedule the treating physician should 
consider the personal aspects of the patient; age, daily activities (work, school, sports), existing 
joint impairments and the patients opinion on treatment. This may for some patients result in a 
reduced use of clotting factor preparations while in others there may be a need for a more 
intense treatment schedule. In chapter 3.1 the association between carriership of hemophilia, 
clotting factor levels and bleeding after interventions was investigated. An awareness of this 
risk of bleeding in carriers by physicians may result in a reduction of the frequency of bleeding. 
Assessment of the clotting factor level of carriers of hemophilia should become a part of the 
standard measurements performed before a medical intervention in these women. Our study 
shows that the risk of bleeding is not only increased in women who would be defined as having 
mild hemophilia, but also in women with clotting factor levels between 0.40 and 0.60 IU/ml. 







We have shown that although well treatable, hemophilia is still a disease affecting life and 
death. We found an excess number of fatal intracranial hemorrhages in patients with 
hemophilia, which has also been reported in a study performed in the UK6. Future studies 
should address whether these deaths can be prevented. Other studies might focus on the risk of 
death related to different treatment strategies (prophylaxis vs. on demand).  
We may also discuss our own raison-d’être: is there a rationale for a sixth Hemophilia in the 
Netherlands survey? Over the years we have gathered a large amount of data and have shown 
the improvements related to the changes in treatment. The introduction of the electronic patient 
file will provide us with the data previously gathered through HiN questionnaires. This will 
enable us to study more precise aspects of treatment.  Another future research project may 
involve expansion of the study into hemorrhagic risk of carriers of hemophilia. To avoid 
misclassification of clotting factor levels we should measure these levels in a standardized way 
and determine factor VIII or IX levels in certified laboratories. By performing a survey prior to 
the carrier testing we might reduce the effect of recall bias.  
 
Although the medical situation of hemophilia has considerably improved over the last three 
decades, through an intensive treatment regimen, there are still many aspects that require 
attention: biological, in medical care and social. The need for continued study of the problems 
of hemophilia is witnessed by the excess risk of mortality in patients, even those without viral 
infections. In this thesis, we intended to give an overview of the current medical and social 
situation of patients with hemophilia. In addition, the results of our study among female carriers 
of the hemophilia gene may lead to an increased awareness by treating physicians about the 
problems they face and the importance of the determination of clotting factor levels in these 





What was already known on this topic? 
 
 
• Since the introduction of replacement therapy in the early 1960s important changes 
have occurred for hemophilia patients.  
 
• Since 1985 clotting factor products have been safe for HIV and since 1992 also for 
the transmission of hepatitis C. Few studies have reported on mortality in the total 
population of hemophilia patients after the period of risk of viral infections 
transmission. 
 
• The uptake of recombinant factor VIII products has been slower in the Netherlands 
compared to other countries.   
 
• Hepatitis C is a major co-morbidity among patients with hemophilia who received 
inadequately or non-virus inactivated clotting factor concentrates before 1992. 
 
• Extensive knowledge is available on bleeding in men with hemophilia; the risk of 








What does this thesis add? 
 
 
• National and international guidelines describing the use of prophylactic treatment 
were not strictly followed. 
 
• A steady decrease was observed in the annual number of hemorrhages, of hospital 
admissions, of duration of stay in hospital and of days absent from school or work. 
 
• Despite intensified treatment limited improvement was observed in self-reported 
impairment of joint function in patients older than 16 years. 
 
• Hepatitis C and AIDS had a large impact on mortality of hemophilia patients.  
 
• Even without virus infections hemophilia patients live a few years less than the 
average Dutch male.  
 
• Although hemophilia patients represent one of the most empowered patient 
groups, physicians' opinions appeared to have been dominant in choosing between 
pdFVIII and rFVIII.  
 
• In the Netherlands 65% of patients received rVIII, this percentage varied widely 
among centres.  
 
• In 2002 the prevalence of hepatitis C among patients with hemophilia who 
received clotting factor products before 1992 was 54%. The majority of patients 
with a current HCV infection had not been treated with antiviral therapy. 
 
• Social functioning was worse in patients with hemophilia than the general male 
population, especially among elder patients.  
 
• Carriers of hemophilia experience more bleeding than non-carriers, especially after 
medical interventions.  
 
• Although in the literature the level of 0.40 IU/ml is used to define mild hemophilia 
and is related to bleeding, we also found increased risk of bleeding in women with 
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Hemophilia is hereditary clotting disorder which is caused by a deficiency of factor VIII 
(hemophilia A) or IX (hemophilia B). Due to the X-chromosomal inheritance pattern patients 
are primarily male, while women can be carriers of the disease.   
 
This thesis aimed to describe changes in both the medical situation and social functioning of 
hemophilia patients. The first part focuses on medical and social functioning of hemophilia 
patients taking into account changes in treatment and the effect of viral infections. In the 
second part the hemorrhagic risk of carriers of hemophilia is evaluated.  
 
In the Netherlands a series of five postal surveys have been performed from 1972 onwards.  
In chapter 2.1 we studied mortality, causes of death and life expectancy of hemophilia 
patients between 1992 and 2001. We performed a prospective cohort study among 967 
patients with hemophilia. The findings were compared with those of previous cohorts, 
together spanning 30-years of observation from 1972 onwards, which shows the period 
before, during and after the use of potentially contaminated clotting products. We observed an 
excess mortality of hemophilia during the last decade. Although currently clotting factor 
products are safe from the Human Immunodeficiency Virus (HIV) and hepatitis C virus 
(HCV), viral infections had a large influence on mortality. AIDS was responsible for the 
largest number of deaths (24% of deaths) and 15% of deaths were due to hepatocellular 
carcinoma or chronic liver disease. Without the effects of HIV and HCV the rate of death 
among patients with severe hemophilia was 1.4-fold higher than expected. The remaining 
excess risk in all likelihood resulted from hemorrhages.  Life expectancy of patients with 




severe hemophilia not affected by hepatitis C or HIV had a life expectancy of 71 years, which 
was still slightly lower than the life expectancy of the Dutch male population of 76 years.  
In chapter 2.2 we investigated the most important medical and social developments over the 
last three decades of hemophilia treatment. In April 2001, we sent questionnaires to all known 
Dutch hemophilia patients, with a response of 70%. We compared different age categories, 
and children were defined as patients younger than 16, adolescents as patients between 16 and 
25 and adults as patients aged above 25 years. Changes in treatment were reflected by an 
increase in the use of prophylaxis; especially in children. The occurrence of hemorrhages has 
gradually decreased. Hospital admissions decreased from 47% of all patients in 1972 to 18% 
in 2001.  Despite intensified treatment limited improvement was observed in self-reported 
impairment of joint function in patients older than 16 years.  
In chapter 2.3 we compared social functioning and health-related quality of life between 
hemophilia patients and the general male population. We assessed data on full-time or part- 
time participation in work, disability and health related quality of life in hemophilia patients 
between 15 and 64 years old. In the analysis we compared our findings with the general 
population, separately for patients born before the introduction of prophylaxis (30-64 years of 
age) and patients born after the introduction of prophylaxis (15-30 years old). Our study 
showed that although important physical improvements had been achieved, hemophilia 
patients were less involved in full time labour and were more often occupationally disabled. 
The involvement in labour seems to be important for quality of life as employed patients had 
a higher quality of life than patients without employment.  
Chapter 2.4 reports on the prevalence of hepatitis C and the use of antiviral therapies during 
the last decade among patients with hemophilia. Hepatitis C is a major co-morbidity among 
patients with hemophilia who received inadequately or non-virus inactivated clotting factor 




population for the present study consisted of 771 patients who had received clotting factor 
products before 1992 of whom 638 reported their hepatitis C status. A total of 441 of the 638 
(68%) patients ever had a positive test for hepatitis C virus (HCV); 344 patients (54%) had a 
current infection, and 97 (15%) had cleared the virus. Among 344 patients currently HCV 
infected, 111 (32%) had received treatment for hepatitis C, while 34% (33/97) of patients with 
an infection in the past had been treated for hepatitis C.  
In 2002 the prevalence of hepatitis C among patients with hemophilia who had received 
clotting factor products before 1992 was 54%. The majority of patients with a current HCV 
infection had not been treated with antiviral therapy.  
In chapter 2.5 the uptake of recombinant factor VIII in the Netherlands was assessed. In 
comparison with other biotech substitutions, the adoption of recombinant Factor VIII (rFVIII) 
has been relatively slow. We sent a postal questionnaire to all Dutch haemophilia patients and 
haemophilia treating physicians, to determine which factors predicted whether a patient used 
plasma derived FVIII (pdFVIII) or rFVIII and to investigate patients’ and doctors’ opinions 
on both products. The use of recombinant FVIII varied widely between centers. Younger 
patients, those not infected with HIV or hepatitis C virus, and those who did not have family 
members who used pdFVIII, switched more often from pdFVIII to rFVIII. Patients who rated 
themselves as innovative, who had family members who used rFVIII, and those who were 
treated in a large hemophilia treatment center, also more often had switched. For physicians 
and patients alike, the respondents generally did not see large differences between rFVIII and 
pdFVIII, except for the risk of infections and the knowledge on long-term effects (both larger 
for pdFVIII). Although hemophilia patients represent one of the most empowered patient 
groups, physicians appear to have been influential in choosing between pdFVIII and rFVIII.  
In chapter 3.1 bleeding in carriers of hemophilia were investigated. A wide range of factor 




lyonisation may lead to low clotting factor levels. A postal survey was performed in all 
women tested for carriership of hemophilia between 1985 and 2001.We compared bleeding 
after trauma and medical interventions in carriers and non-carriers. Clotting factor levels 
lower than 0.60 IU/ ml were increasingly associated with prolonged bleeding from small 
wounds, prolonged bleeding after tooth extraction, tonsillectomy and operations. We showed 
that carriers of hemophilia have a higher risk of bleeding compared to non-carriers especially 



























Hemofilie is een zeldzame aandoening. In Nederland bedraagt de prevalentie 8 á 9 per  
100, 000 inwoners. Dit komt in Nederland neer op ongeveer 1600 patiënten. Van deze 
patiënten heeft het merendeel (85%) hemofilie A (een tekort aan stollingsfactor VIII) en het 
overige deel hemofilie B (een tekort aan stollingsfactor IX).  
Hemofilie is een recessief geslachtsgebonden erfelijke aandoening en komt vrijwel uitsluitend 
bij mannen voor. De ernst van de aandoening wordt bepaald door de residuele activiteit van 
de stollingsfactor. Ongeveer de helft van de patiënten heeft een ernstige vorm van hemofilie, 
dat wil zeggen dat minder dan 1% van de normale concentratie van de stollingsfactor in het 
bloed aanwezig is. Deze vorm wordt gekenmerkt door het optreden van spontane of door 
geringe traumata geïnduceerde, grote bloedingen. De lichte vorm van hemofilie wordt 
gekenmerkt door aanwezigheid van enige stollingsfactor in het bloed. Bloedingen treden in 
dit geval meestal op bij kiesextracties, operaties, ongevallen of na  grote sportieve prestaties 
of krachtsinspanningen.  
Hemofilie wordt behandeld door toediening van stollingsfactorconcentraat, de zgn. substitutie 
therapie. Wanneer de therapie erop gericht is het aantal bloedingen sterk terug te brengen  of 
zelfs geheel te voorkomen, spreekt men van profylactische therapie. De profylactische 
toediening van stollingsfactorconcentraat gebeurt veelal thuis. Tegenover profylactische 
behandeling staat de zgn. ‘on demand’ therapie, waarbij alleen stollingsfactorconcentraat 
wordt toegediend in geval van een bloeding. Elke bloeding dient dan zo snel mogelijk te 
worden behandeld met een voldoende hoge dosering van de ontbrekende stollingsfactor.  
Hemofilie is in Nederland een van de best beschreven zeldzame aandoeningen. Het Hemofilie 
in Nederland onderzoek (HiN) heeft hier een belangrijke bijdrage aan geleverd. Het HiN 




uitgevoerd in 1972 onder leiding van professor dr J. Veltkamp. Sinds dit eerste onderzoek is 
de HiN studie vier keer herhaald, in 1978, 1985, 1992 en in 2001.  
Dit proefschrift beschrijft de resultaten van het Hemofilie in Nederland-5 onderzoek. 
Daarnaast werd het bloedingsrisico bij vrouwelijke familieleden van hemofiliepatiënten 
onderzocht.  
 
Hoofdstuk 2.1 beschrijft de resultaten van een prospectief vervolgonderzoek onder patiënten 
met hemofilie A en B naar sterfte, levensverwachting en doodsoorzaken tussen 1992 en 2001.  
onze resultaten hebben wij vergeleken met eerder perioden van follow-up om een beeld te 
geven van de periode voor, tijdens en na het gebruik van mogelijk met virusinfecties besmette 
stollingsproducten. De sterftecijfers zijn vergeleken met de algemene Nederlandse mannelijke 
bevolking. Hierbij kwam naar voren dat hemofilie nog steeds gepaard gaat met  oversterfte. 
De belangrijkst doodsoorzaken waren AIDS en levercarcinoom en levercirrhose als gevolg 
van hepatitis C. Opvallend was dat in patiënten met ernstige hemofilie zonder besmetting met 
HIV(humaan immunodeficiëntie virus) of het hepatitis C virus de kans op sterfte nog steeds 
hoger was dan de algemene populatie. De levensverwachting van deze patiënten was 71 jaar, 
in vergelijking  met 76 jaar in de algemene bevolking. Dit betekent dat de huidige patiënt wel 
profiteert van een behandeling met veilige stollingsproducten, maar de levensverwachting nog 
steeds negatief beïnvloed wordt door de stollingsafwijking.  
Hoofdstuk 2.2 beschrijft de medische en sociale ontwikkelingen gedurende 30 jaar 
hemofiliebehandeling. Wij hebben alle in 2001 in Nederland bekende hemofiliepatiënten een 
vragenlijst gestuurd, waarbij ongeveer 70% van hen bereid was deel te nemen. De vragenlijst 
bestond uit twee delen; een algemeen deel en een specifiek deel. Het algemene deel bestond 
uit vragen die gelijk waren aan die uit eerdere vragenlijsten, o.a. over bloedingfrequentie, 




hemofiliebehandelcentra en de keuze tussen recombinant en plasma stollingsproducten 
behandeld. Uit ons onderzoek is gebleken dat het gebruik van profylactische therapie vooral 
bij kinderen en adolescenten is toegenomen. Oudere patiënten combineren veelal ‘on demand’ 
behandeling met profylaxe op risicovolle dagen. De verbeterde therapeutische mogelijkheden 
hebben geleid tot een afname in het jaarlijks aantal bloedingen, het percentage patiënten dat 
opgenomen moest worden in een ziekenhuis en het aantal dagen dat patiënten afwezig waren 
van school of werk.  Een opvallende bevinding in dit onderzoek was dat ondanks een 
intensieve behandeling patiënten van 16 jaar en ouder beperkingen in gewrichten die 
rapporteren.  
Het sociaal functioneren en de kwaliteit van leven van patiënten met hemofilie wordt 
beschreven in hoofdstuk 2.3. Sinds de introductie van stollingsfactorconcentraat is er veel 
verbeterd voor mensen met hemofilie. Behalve ‘on demand’ kan behandeling ook 
profylactisch worden gegeven. De verwachting bestaat dat wanneer alle bloedingen 
voorkomen kunnen worden met profylaxe, patiënten met hemofilie een volledig normaal 
bestaan kunnen leven. Ons onderzoek studie toont aan dat de deelname aan het arbeidsproces 
vooral voor patiënten met ernstige hemofilie lager is dan in de algemene mannelijke 
populatie. Dit was zowel het geval voor jonge mannen die hun leven lang met profylaxe zijn 
behandeld als voor oudere mannen bij wie deze behandeling pas later is begonnen. Hierbij 
leek er een verband te zijn tussen deelname aan het arbeidsproces en kwaliteit van leven: 
patiënten die geen werk hadden, rapporteerden een lagere kwaliteit van leven. Het verschil in 
kwaliteit van leven tussen hemofiliepatiënten en de Nederlandse bevolking was groter in 
oudere patiënten. Ondanks een verbeterde behandeling is de deelname aan het arbeidsproces 
van hemofiliepatiënten nog niet op het niveau van de Nederlandse man.  
In hoofdstuk 2.4 werd in de HiN-5 studie de prevalentie van hepatitis C en het gebruik van 




behandeld met onveilige stollingsproducten belangrijke co-morbiditeit. De studiepopulatie 
bestond uit deelnemers aan de HiN-5 studie die voor 1992 behandeling hebben ontvangen. 
Van deze patiënten was 54% op dit moment hepatitis C positief, van wie 32% werd behandeld 
met antivirale therapie. Om de betrouwbaarheid van de gerapporteerde data te controleren is 
een validiteitsanalyse uitgevoerd. Deze analyse bevestigde onze aanname dat patiënten met 
hemofilie goed geïnformeerd zijn over hun aandoening en de verwante complicaties. Met ons 
onderzoek hebben wij aangetoond dat hepatitis C nog steeds een belangrijke co-morbiditeit is 
en dat slechts een minderheid van de patiënten zich laat behandelen. Belangrijke redenen voor 
afzien van behandeling waren de onzekerheid over de lange termijn effecten en de effectiviteit 
van de behandeling.   
Hoofdstuk 2.5 behandelt de introductie van recombinant Factor VIII (rFVIII) als een 
alternatief voor uit plasma gewonnen Factor VIII (pFVIII) voor de behandeling van hemofilie 
A. We vonden dat het verspreidingspatroon voor een groot deel werd bepaald door de 
Nederlandse Vereniging van Hemofilie Behandelaren, die had besloten tot een geleidelijke 
introductie van rFVIII. De hemofiliebehandelaren kwamen tevens overeen dat voorheen 
onbehandelde patiënten bij voorkeur zouden worden behandeld met rVIII. De enquête wees 
uit dat beide afspraken grotendeels zijn nageleefd. Zowel artsen als patiënten gaven aan dat de 
arts en niet de patiënt de meeste invloed heeft op de keuze voor een bepaald type FVIII 
product. In totaal schreven de artsen pFVIII voor aan 56% van hun patiënten, en de variatie in 
dit percentage per arts was groot. De artsen gaven aan dat leeftijd de enige factor was die een 
rol speelde bij de productkeuze voor een bepaalde patiënt. Een infectie met HIV, infectie met 
het hepatitis C virus, en het gegeven dat iemand familieleden had die pVIII gebruikten waren 
negatief geassocieerd met het overstappen van pFVIII naar rFVIII.  
Hoewel een uitgebreide kennis bestaat over bloedingen bij mannen met hemofilie heeft niet 




behandeld in hoofdstuk 3. In dit hoofdstuk bestuderen we de kans op bloeden onder 
draagsters van hemofilie A of B in vergelijking met niet-draagsters. Voor dit onderzoek 
hebben alle vrouwen die getest zijn op draagsterschap in het Leids Universitair Medisch 
Centrum of het Universitair Medisch Centrum Utrecht een vragenlijst ontvangen. 
Draagsterschaponderzoek voor hemofilie beperkt zich in Nederland voornamelijk tot deze 
centra.  Tevens zijn gegevens verzameld met betrekking tot factor VIII en IX levels. We 
hebben zowel draagsterschap als stollingsfactorniveaus geassocieerd met het risico van 
bloeden. Onze studie toont aan dat draagsters van hemofilie een grotere kans hebben op 
bloedingen, vooral na medische interventies zoals operaties en tandextracties. Daarnaast is 
gebleken dat niet alleen stollingsfactorniveaus die vergelijkbaar zijn met de niveaus bij lichte 
hemofilie geassocieerd zijn met bloeden, maar ook hogere niveaus tussen 0.4 en 0.6 IU ml. 
Dit suggereert dat de als "veilig" aangenomen stollingsniveaus wellicht herzien moeten 
worden.  
 
Deze studie laat zien dat hoewel de situatie van hemofiliepatiënten op medisch gebied 
verbeterd is door een intensievere behandeling, er nog veel aspecten zijn waar aandacht aan 
besteed dient te worden. De oversterfte in patiënten zonder virale infecties is hier een 
voorbeeld van. Wij hopen met deze studie een beeld te hebben gegeven van de medische en 
sociale omstandigheden van mensen met hemofilie. Belangrijk zijn ook de resultaten uit het 
onderzoek onder vrouwelijke familieleden van mannen met hemofilie. Wij hopen dat de 
resultaten van deze studie zullen leiden tot een verbeterd inzicht onder artsen van het belang 









Tijdens je promotieperiode leer je heel wat mensen kennen. Ondanks dat een nawoord 
te kort is om iedereen de credits te geven die ze verdienen, wil ik toch van deze 
gelegenheid gebruik maken om een aantal mensen in het bijzonder noemen. In 
oktober 2000 ben ik als promovendus onder leiding van prof. dr Frits Rosendaal 
gestart op het Hemofilie in Nederland-5 onderzoek. Op dat moment was het van groot 
belang om het onderzoek zo snel mogelijk op de rails te krijgen. Doeltreffende hulp is 
dan onmisbaar. Inge, je hebt mij in korte tijd de fijne kneepjes van datamanagement 
bijgebracht. Vooral in het begin was jij een steun met alle kennis over Access, 
scannen en de logistiek rond vragenlijsten.  
Yvonne Souverein, de spil van de afdeling Klinische Epidemiologie, bedankt dat je 
altijd voor ons klaarstaat en weer een plekje vindt in overvolle agenda's. De 
mogelijkheid om je ervaringen te delen met andere promovendi is een belangrijk 
onderdeel van je promotie, daarom Carla, Astrid, Sverre en alle anderen bedankt voor 
de gezelligheid, maar ook voor alle tips op het gebied van SPSS en analyses. Carine, 
je hebt me veel geleerd over het geven van onderwijs en je enthousiasme was en is erg 
stimulerend. Anske, ik vind het heel bijzonder dat je in korte tijd zo’n belangrijke 
bijdrage hebt weten te leveren aan mijn proefschrift. Ik heb onze discussies en jouw 
altijd uitgebreide commentaar zeer gewaardeerd. Jeanet, ik vond het een onwijs 
gezellige tijd met jou als kamergenoot. We hebben heel wat gelachen en vaak waren 
ook de serieuze gesprekken niet van de lucht. Bedankt dat jij mijn paranimf wilt zijn.  
Natuurlijk gaan mijn wensen ook uit naar al mijn andere collega’s van de Klinische 
Epidemiologie, bij iedereen is er altijd even tijd om binnen te lopen en ook de 
belangstelling voor elkanders persoonlijk leven vind ik heel waardevol.  
Heel wat mensen van buiten de afdeling hebben bijgedragen aan een plezierige 
promotieperiode. Allereerst de leden van de HiN-5 werkgroep, jullie hebben er met 
jullie enthousiasme voor gezorgd dat ik me erg thuis ben gaan voelen binnen het 
hemofiliewereldje. Arja, bedankt dat je me hebt geïntroduceerd binnen de hemofilie 
vakantiekampen en voor je gastvrijheid tijdens de spreekuren, ik heb er erg veel van 
geleerd. De Nederlandse Vereniging van Hemofiliepatiënten (NVHP) en haar 
medewerkers hebben mij de mogelijkheid gegeven om contact te leggen met 
patiënten,  niet alleen op patiëntenbijeenkomsten, maar ook via de Faktor.  
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Alle mensen van de Van Creveldkliniek en in het bijzonder Dirk en Karin, bedankt 
voor jullie gastvrijheid.  
Tenslotte, natuurlijk mijn familie en vrienden voor hun belangstelling voor mijn werk. 
Arie, de samenwerking in het ontwerp van de voorkant van mijn boekje was erg leuk. 
Ik heb grote waardering voor de manier waarop je erin slaagt bloemen ook op papier 
te laten leven. Mijn schoonouders, Martijn en schoonzussen bedankt voor jullie steun 
en vriendschap. Pa en ma, jullie hadden altijd het vertrouwen dat het zeker zou lukken 
en jullie hebben gelijk gekregen, bedankt voor de soms strenge maar bemoedigende 
woorden en voor de levendige discussies. Marco, ik vind het bijzonder dat jij als 
paranimf naast mij zult staan in mijn promotie. Vincent, jouw rust en luisterend oor 
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